Unnamed: 0,title,date,stock,sentiment
877688.0,Myriad Genetics Highlights Study Of GeneSight Psychotropic Published In Psychiatry Research Journal,2020-06-08 07:06:00-04:00,MYGN,neutral
877689.0,Myriad Genetics Highlights Publication Of Prospective Clinical Study Of EndoPredict Test In Women With Early-Stage Breast Cancer,2020-06-04 07:09:00-04:00,MYGN,negative
877690.0,Myriad Genetics Highlights New Data To Be Presented At ASCO On riskscore For Personalized Breast Cancer Risk Information to Patients,2020-05-29 07:12:00-04:00,MYGN,negative
877691.0,"Cerecor And Myriad Genetics Announce  'Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study '",2020-05-26 07:16:00-04:00,MYGN,positive
877692.0,"The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test",2020-05-20 08:12:00-04:00,MYGN,neutral
877693.0,Myriad Genetics shares are trading higher after the company announced it has received FDA approval for BRACAnalysis CDx as a companion diagnostic for Lynparza for the treatment of adult patients with metastatic castration-resistant prostate cancer.,2020-05-20 07:32:00-04:00,MYGN,neutral
877694.0,Myriad Receives FDA Approval Of BRACAnalysis CDx As A Companion Diagnostic For Lynparza In HRR-Mutated Metastatic Castration-Resistant Prostate Cancer,2020-05-20 07:07:00-04:00,MYGN,negative
877695.0,Myriad Genetics shares are trading higher after the company announced it has received FDA approval for the company's myChoice CDx-test as a companion diagnostic for Lynparza in patients with advanced ovarian cancer.,2020-05-11 07:36:00-04:00,MYGN,positive
877696.0,15 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-05-11 07:36:00-04:00,MYGN,neutral
877697.0,Myriad Receives FDA Approval Of myChoice CDx As Companion Diagnostic For Lynparza In Patients With Advanced Ovarian Cancer,2020-05-11 07:06:00-04:00,MYGN,negative
877698.0,"JP Morgan Maintains Underweight on Myriad Genetics, Lowers Price Target to $12",2020-05-06 10:48:00-04:00,MYGN,positive
877699.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,MYGN,positive
877700.0,33 Stocks Moving in Wednesday's Pre-Market Session,2020-05-06 07:15:00-04:00,MYGN,neutral
877701.0,10 Stocks Moving In Tuesday's After-Hours Session,2020-05-05 17:43:00-04:00,MYGN,neutral
877702.0,Myriad Genetics shares are trading lower after the company reported worse-than-expected Q3 EPS and sales results.,2020-05-05 16:52:00-04:00,MYGN,neutral
877703.0,"Myriad Genetics Q3 EPS $(0.080) Misses $0.020 Estimate, Sales $164.000M Miss $167.190M Estimate",2020-05-05 16:28:00-04:00,MYGN,negative
877704.0,Myriad Genetics Option Alert: May 15 $17 Calls at the Ask: 1000 @ $1.7 vs 1052 OI; Earnings 5/5 After Close Ref=$15.6,2020-05-05 10:50:00-04:00,MYGN,positive
877705.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,MYGN,positive
877706.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,MYGN,neutral
877707.0,Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight Psychotropic Test in People with Major Depressive Disorder,2020-04-20 07:08:00-04:00,MYGN,negative
877708.0,Shares of several healthcare companies are trading higher amid optimistic coronavirus outlook following positive drug data from Gilead. This has raised hopes of a sooner return to spending and economic activity.,2020-04-17 10:04:00-04:00,MYGN,positive
877709.0,"The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO",2020-04-08 07:53:00-04:00,MYGN,neutral
877710.0,Myriad Withdrawing FY20 Guidance,2020-04-08 07:05:00-04:00,MYGN,neutral
877711.0,84 Biggest Movers From Yesterday,2020-04-07 05:47:00-04:00,MYGN,neutral
877712.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 09:42:00-04:00,MYGN,positive
877713.0,Myriad Receives Reimbursement For BRACAnalysis Diagnostic System In Japan For Patients With Breast Or Ovarian Cancer Associated With HBOC,2020-04-06 07:24:00-04:00,MYGN,negative
877714.0,"B of A Securities Reiterates Underperform on Myriad Genetics, Lowers Price Target to $13",2020-04-02 08:41:00-04:00,MYGN,positive
877715.0,Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis Diagnostic System in People with Advanced Pancreatic and Prostate Cancer,2020-03-30 07:06:00-04:00,MYGN,negative
877716.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,MYGN,positive
877717.0,"Barclays Maintains Underweight on Myriad Genetics, Lowers Price Target to $10",2020-03-26 10:56:00-04:00,MYGN,negative
877718.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,MYGN,neutral
877719.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,MYGN,positive
877720.0,Myriad's Says NCCN Updated Professional Guidelines Recommending Biomarker Testing For Unfavorable Intermediate And High-Risk Prostate Cancer Patients; Notes Co.'s Prolaris Test Was 'one of only two prognostic tests for prostate cancer' Recommended,2020-03-18 07:14:00-04:00,MYGN,negative
877721.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,MYGN,neutral
877722.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,MYGN,negative
877723.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,MYGN,negative
877724.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,MYGN,negative
877725.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,MYGN,positive
877726.0,Stocks That Hit 52-Week Lows On Tuesday,2020-03-10 10:37:00-04:00,MYGN,negative
877727.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,MYGN,negative
877728.0,Stocks That Hit 52-Week Lows On Friday,2020-03-06 11:22:00-05:00,MYGN,negative
877729.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,MYGN,negative
877730.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,MYGN,neutral
877731.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,MYGN,negative
877732.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,MYGN,positive
877733.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,MYGN,negative
877734.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,MYGN,negative
877735.0,Myriad Genetics Shares Spike To Session High As Hearing Co. Wins Aetna Insurance Coverage For Its BRACAnalysis CDx Diagnostic,2020-02-18 13:43:00-05:00,MYGN,positive
877736.0,Myriad Genetics Highlights Presentation Of New Data On Ability Of Prolaris To Predict Men With Prostate Cancer At American Society of Clinical Oncology Genitouranary Cancer Symposium,2020-02-14 07:07:00-05:00,MYGN,negative
877737.0,Myriad Submits sPMA For myChoice CDx With Lynparza In First-Line Maintenance Therapy In Advanced Ovarian Cancer,2020-02-11 07:14:00-05:00,MYGN,negative
877738.0,30 Stocks Moving in Monday's Pre-Market Session,2020-02-10 07:30:00-05:00,MYGN,neutral
877739.0,95 Biggest Movers From Friday,2020-02-10 05:20:00-05:00,MYGN,neutral
877740.0,Mid-Afternoon Market Update: Dow Falls Over 300 Points; Assertio Therapeutics Shares Spike Higher,2020-02-07 14:30:00-05:00,MYGN,positive
877741.0,"Mid-Morning Market Update: Markets Open Lower; US Adds 225,000 Jobs For January",2020-02-07 10:10:00-05:00,MYGN,negative
877742.0,2 Diagnostics & Research Stocks Moving In Friday's Pre-Market Session,2020-02-07 07:41:00-05:00,MYGN,neutral
877743.0,16 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-02-07 07:39:00-05:00,MYGN,neutral
877744.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,MYGN,negative
877745.0,46 Stocks Moving in Friday's Pre-Market Session,2020-02-07 07:25:00-05:00,MYGN,neutral
877746.0,"Myriad Genetics shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results. The company also reported the President and CEO, Mark Capone, resigned.",2020-02-07 07:19:00-05:00,MYGN,negative
877747.0,29 Stocks Moving In Thursday's After-Hours Session,2020-02-06 17:23:00-05:00,MYGN,neutral
877748.0,"Myriad Genetics shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results. The company also reported the President and CEO, Mark Capone, resigned.",2020-02-06 16:33:00-05:00,MYGN,negative
877749.0,"Myriad Genetics Reports Pres, CEO Mark Capone Resigned; CFO R. Bryan Riggsbee Named Interim Replacement",2020-02-06 16:25:00-05:00,MYGN,negative
877750.0,"Myriad Genetics Sees Q3 Adj. EPS $0.02 vs $0.30 Estimate, Sales $172M vs $201M Est.; FY20 Adj. EPS $0.45 vs $1.06 Est., Sales $735M vs $807M Est.",2020-02-06 16:21:00-05:00,MYGN,neutral
877751.0,"Myriad Genetics Q2 Adj. EPS $0.23 Misses $0.31 Estimate, Sales $195.1M Miss $209.81M Estimate",2020-02-06 16:20:00-05:00,MYGN,negative
877752.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,MYGN,negative
877753.0,"Earnings Scheduled For February 6, 2020",2020-02-06 04:30:00-05:00,MYGN,neutral
877754.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,MYGN,neutral
877755.0,Gene-editing/sequencing stocks trading higher following finalization of national coverage decision by Centers for Medicare & Medicaid Services related to next-gen sequencing.,2020-01-28 12:35:00-05:00,MYGN,neutral
877756.0,Myriad Genetics Submits sPMA for myChoice CDx with Zejula in First-Line Platinum Responsive Advanced Ovarian Cancer,2020-01-23 05:14:00-05:00,MYGN,negative
877757.0,Myriad Submits sPMA For BRACAnalysis CDx As A Companion Diagnostic For Lynparza In Metastatic Castration-resistant Prostate Cancer,2020-01-21 07:05:00-05:00,MYGN,negative
877758.0,Enzo Biochem Responds to Statements From Activist Hedge Fund Harbert,2020-01-13 08:09:00-05:00,MYGN,neutral
877759.0,"Benzinga's Top Upgrades, Downgrades For January 3, 2020",2020-01-03 11:33:00-05:00,MYGN,positive
877760.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-30 08:21:00-05:00,MYGN,neutral
877761.0,25 Stocks Moving in Monday's Pre-Market Session,2019-12-30 07:47:00-05:00,MYGN,neutral
877762.0,Myriad Receives FDA Approval Of BRACAnalysis CDx As Companion Diagnostic For Lynparza In Patients With Germline BRCA-mutated Metastatic Pancreatic Cancer,2019-12-30 07:07:00-05:00,MYGN,negative
877763.0,51 Biggest Movers From Tuesday,2019-12-26 05:14:00-05:00,MYGN,neutral
877764.0,33 Stocks Moving In Tuesday's Mid-Day Session,2019-12-24 11:34:00-05:00,MYGN,neutral
877765.0,Myriad Genetics shares are trading higher on a potential rebound following the ~10% dip yesterday.,2019-12-24 10:17:00-05:00,MYGN,positive
877766.0,78 Biggest Movers From Yesterday,2019-12-24 04:32:00-05:00,MYGN,neutral
877767.0,44 Stocks Moving In Monday's Mid-Day Session,2019-12-23 12:19:00-05:00,MYGN,neutral
877768.0,"Myriad Genetics shares are trading lower. Not currently seeing any company-specific news. Traders circulate bearish Motley Fool article comparing the stock to peer Exact Sciences, which it says expects to 'deliver significantly more growth in the future.'",2019-12-23 12:02:00-05:00,MYGN,neutral
877769.0,Myriad Genetics Option Alert: May 15 $23 Puts Sweep (33) near the Bid: 557 @ $2.351 vs 11 OI; Earnings 2/4 After Close [est] Ref=$24.8099,2019-12-23 11:56:00-05:00,MYGN,positive
877770.0,Myriad Genetics Highlights Publication Of New Study Of Its Prequel PRenatal Screen In Prenatal Diagnosis Journal,2019-12-04 07:09:00-05:00,MYGN,neutral
877771.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,MYGN,negative
877772.0,"Myriad Genetics Reports Japan's Ministry Of Health, Labour, Welfare Approved BRACAnalysis System",2019-11-21 07:09:00-05:00,MYGN,positive
877773.0,Myriad Announces Prequel Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening -,2019-11-11 07:12:00-05:00,MYGN,neutral
877774.0,Myriad Genetics shares are trading higher after the company announced data from the GUIDED clinical trial showed GeneSight Psychotropic test improved clinical outcomes for people with depression who were taking medications with gene-drug interactions.,2019-11-06 11:45:00-05:00,MYGN,positive
877775.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,MYGN,positive
877776.0,Myriad Genetics Highlights Results From New Analysis Of GUIDED Clinical Trial Published In Journal Of Clinical Psychiatry Showing Its GeneSight Psychotropic Test Improved Clinical Outcomes In Patients Taking Medications With Gene-Drug Interactions,2019-11-06 07:08:00-05:00,MYGN,positive
877777.0,61 Biggest Movers From Yesterday,2019-11-06 04:19:00-05:00,MYGN,neutral
877778.0,Mid-Afternoon Market Update: Dow Gains 80 Points; Fulgent Genetics Shares Jump Following Strong Q3 Results,2019-11-05 14:26:00-05:00,MYGN,positive
877779.0,Mid-Day Market Update: EverQuote Rises After Upbeat Q3 Results; Armstrong Flooring Shares Plummet,2019-11-05 12:20:00-05:00,MYGN,positive
877780.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-11-05 12:10:00-05:00,MYGN,neutral
877781.0,Stocks That Hit 52-Week Lows On Tuesday,2019-11-05 11:18:00-05:00,MYGN,negative
877782.0,Mid-Morning Market Update: Markets Mixed; Emerson Electric Profit Beats Views,2019-11-05 10:15:00-05:00,MYGN,positive
877783.0,Myriad Genetics shares are trading lower after the company reported Q1 EPS of $0.08 compared to the $0.32 estimate and worse-than-expected Q1 sales results. The company also issued Q2 and FY20 EPS and sales guidance below analyst estimates.,2019-11-05 07:59:00-05:00,MYGN,neutral
877784.0,10 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-11-05 07:33:00-05:00,MYGN,neutral
877785.0,24 Stocks Moving in Tuesday's Pre-Market Session,2019-11-05 07:23:00-05:00,MYGN,neutral
877786.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,MYGN,negative
877787.0,Myriad Genetics shares are trading lower after the company reported Q1 EPS of $0.08 compared to the $0.32 estimate and worse-than-expected Q1 sales results. The company also issued Q2 and FY20 EPS and sales results below analyst estimates.,2019-11-04 16:57:00-05:00,MYGN,neutral
877788.0,"Myriad Genetics Sees FY20 Adj. EPS $1-$1.10 vs $1.82 Estimate, Sales $800M-$810M vs $872.4M Est.",2019-11-04 16:17:00-05:00,MYGN,neutral
877789.0,"Myriad Genetics Sees Q2 Adj. EPS $0.30-$0.32 vs $0.48 Estimate, Sales $210M-$212M vs $221.4M Est.",2019-11-04 16:17:00-05:00,MYGN,neutral
877790.0,"Myriad Genetics Q1 Adj. EPS $0.08 May Not Compare To $0.32 Estimate, Sales $186.3M Miss $202.1M Estimate",2019-11-04 16:16:00-05:00,MYGN,negative
877791.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,MYGN,neutral
877792.0,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",2019-10-24 07:36:00-04:00,MYGN,neutral
877793.0,Myriad Genetics Reports FDA Approval Of myChoice CDx Test,2019-10-23 17:49:00-04:00,MYGN,positive
877794.0,InVitae Shares Bounce Back Following Analyst Rebuttal To Short Seller Allegations,2019-10-17 11:17:00-04:00,MYGN,positive
877795.0,"Benzinga's Top Upgrades, Downgrades For September 26, 2019",2019-09-26 09:40:00-04:00,MYGN,positive
877796.0,Bank of America Downgrades Myriad Genetics to Underperform,2019-09-26 06:38:00-04:00,MYGN,neutral
877797.0,"Myriad Genetics shares are trading lower despite no company-specific news. Stocks in the broader healthcare space have been volatile amid the 2020 Democratic primaries, in which healthcare policy has been a key issue.",2019-09-25 10:51:00-04:00,MYGN,positive
877798.0,58 Biggest Movers From Yesterday,2019-09-25 04:54:00-04:00,MYGN,neutral
877799.0,"Myriad Genetics shares are trading higher. Unconfirmed reports say a Piper Jaffray analyst suggested Genomind, a competitor, resumed including specific drug recommendations in physician reports.",2019-09-24 14:14:00-04:00,MYGN,positive
877800.0,"Myriad Genetics Shares Up 3.6% Over Last 30 Mins As Hearing Piper Jaffray Analyst Suggested A Co. Competitor, Genomind, Resumed Including Specific Drug Recommendations In Physician Reports",2019-09-24 12:18:00-04:00,MYGN,positive
877801.0,Bearish Blog Post Says Sees 45% Downside Risk In Myriad Genetics,2019-09-24 09:40:00-04:00,MYGN,negative
877802.0,"Myriad Genetics Reports Research Collaboration With University Of Leeds, No Terms Disclosed",2019-09-16 07:13:00-04:00,MYGN,negative
877803.0,Myriad Genetics Highlights Publication Of Study Results Showing Effectiveness Of Prolaris Genetic Test In Men With Low-Risk Prostate Cancer,2019-09-05 14:17:00-04:00,MYGN,negative
877804.0,"Hearing Piper Says Buy Myriad Genetic, Saying Medicare News Increase Target Market; Unconfirmed",2019-08-22 14:44:00-04:00,MYGN,positive
877805.0,33 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-08-19 08:47:00-04:00,MYGN,neutral
877806.0,"Barron's Picks And Pans: American Eagle Outfitters, Chevron, Grocery Outlet And More",2019-08-17 13:52:00-04:00,MYGN,neutral
877807.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,MYGN,negative
877808.0,Myriad Genetics Option Alert: Sep 20 $28 Calls at the Ask: 2500 @ $0.651 vs 113 OI; Ref=$22.87,2019-08-15 13:41:00-04:00,MYGN,positive
877809.0,61 Biggest Movers From Yesterday,2019-08-15 05:57:00-04:00,MYGN,neutral
877810.0,Mid-Afternoon Market Update: Dow Falls Over 700 Points; Myriad Genetics Shares Plummet,2019-08-14 14:41:00-04:00,MYGN,positive
877811.0,48 Stocks Moving In Wednesday's Mid-Day Session,2019-08-14 12:50:00-04:00,MYGN,neutral
877812.0,Mid-Day Market Update: Crude Oil Down Over 5%; Purple Innovation Shares Rises After Q2 Results,2019-08-14 12:14:00-04:00,MYGN,neutral
877813.0,Mid-Morning Market Update: Markets Open Lower; Macy's Misses Q2 Estimates,2019-08-14 10:18:00-04:00,MYGN,negative
877814.0,"Benzinga's Top Upgrades, Downgrades For August 14, 2019",2019-08-14 10:00:00-04:00,MYGN,positive
877815.0,What Caused The Opening Gap In Myriad Genetics?,2019-08-14 09:51:00-04:00,MYGN,neutral
877816.0,10 Biggest Price Target Changes For Wednesday,2019-08-14 09:11:00-04:00,MYGN,neutral
877817.0,32 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-08-14 08:50:00-04:00,MYGN,neutral
877818.0,"Deutsche Bank Maintains Hold on Myriad Genetics, Lowers Price Target to $35",2019-08-14 08:18:00-04:00,MYGN,negative
877819.0,31 Stocks Moving In Wednesday's Pre-Market Session,2019-08-14 07:51:00-04:00,MYGN,neutral
877820.0,"The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering",2019-08-14 07:50:00-04:00,MYGN,negative
877821.0,Myriad Genetics shares are trading lower after the company reported worse-than-expected Q4 EPS and sales results. The company also issued Q1 and FY20 guidance below analyst estimates.﻿,2019-08-14 07:07:00-04:00,MYGN,neutral
877822.0,"Piper Jaffray Downgrades Myriad Genetics to Equal-Weight, Lowers Price Target to $40",2019-08-14 07:05:00-04:00,MYGN,negative
877823.0,A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street,2019-08-14 06:59:00-04:00,MYGN,negative
877824.0,"8 Stocks To Watch For August 14, 2019",2019-08-14 05:17:00-04:00,MYGN,neutral
877825.0,10 Stocks Moving In Tuesday's After-Hours Session,2019-08-13 16:49:00-04:00,MYGN,neutral
877826.0,Myriad Genetics shares are trading lower after the company reported worse-than-expected Q4 EPS and sales results. The company issued Q1 and FY20 EPS and sales guidance below analyst estimates.,2019-08-13 16:06:00-04:00,MYGN,neutral
877827.0,"Myriad Genetics Sees Q1 Adj. EPS $0.30-$0.32 vs $0.42 Est., Sales $200M-$202M vs $217.35M Est.; Sees FY20 Adj. EPS $1.80-$1.90 vs $1.92 Est., Sales $865M-$875M vs $921.99M Est.",2019-08-13 16:04:00-04:00,MYGN,neutral
877828.0,"Myriad Genetics Q4 Adj. EPS $0.41 Misses $0.47 Estimate, Sales $215.4M Miss $221.04M Estimate",2019-08-13 16:03:00-04:00,MYGN,negative
877829.0,Myriad Genetics Q4 Earnings Preview,2019-08-13 07:46:00-04:00,MYGN,neutral
877830.0,"The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results",2019-08-13 07:25:00-04:00,MYGN,neutral
877831.0,"Earnings Scheduled For August 13, 2019",2019-08-13 04:11:00-04:00,MYGN,neutral
877832.0,"The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO",2019-08-11 15:46:00-04:00,MYGN,positive
877833.0,Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer,2019-08-07 07:06:00-04:00,MYGN,negative
877834.0,"Deutsche Bank Maintains Hold on Myriad Genetics, Raises Price Target to $45",2019-08-05 08:54:00-04:00,MYGN,neutral
877835.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Fri., August 2, 2019",2019-08-02 14:05:00-04:00,MYGN,positive
877836.0,"A Look At Benzinga Pro's Most-Searched Tickers For August 2, 2019",2019-08-02 12:07:00-04:00,MYGN,neutral
877837.0,Myriad Genetics Shares Tick To Session High Following Unusual Option Activity: Aug. Monthly $48 Calls At The Bid Showing Volume Of 500 Contracts vs Open Interest 5 Contracts,2019-08-02 11:12:00-04:00,MYGN,positive
877838.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Friday., August 2, 2019",2019-08-02 10:35:00-04:00,MYGN,positive
877839.0,"Benzinga's Top Upgrades, Downgrades For August 2, 2019",2019-08-02 09:40:00-04:00,MYGN,positive
877840.0,Bank of America Upgrades Myriad Genetics to Neutral,2019-08-02 08:32:00-04:00,MYGN,neutral
877841.0,100 Biggest Movers From Yesterday,2019-08-02 05:53:00-04:00,MYGN,neutral
877842.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Thu., August 1, 2019",2019-08-01 15:04:00-04:00,MYGN,positive
877843.0,Mid-Afternoon Market Update: U.S. Stocks Turn Lower; Crude Oil Falls Over 8%,2019-08-01 14:31:00-04:00,MYGN,negative
877844.0,Myriad Genetics Shares Jump To 9-Month High On Insurance Coverage For Genetic Test,2019-08-01 13:36:00-04:00,MYGN,positive
877845.0,Mid-Day Market Update: Crude Oil Down Over 3%; SunPower Shares Spike Higher,2019-08-01 13:08:00-04:00,MYGN,negative
877846.0,72 Stocks Moving In Thursday's Mid-Day Session,2019-08-01 12:16:00-04:00,MYGN,neutral
877847.0,Mid-Morning Market Update: Markets Open Higher; General Motors Earnings Top Expectations,2019-08-01 10:14:00-04:00,MYGN,positive
877848.0,Myriad Genetics shares trading higher following news UnitedHealthcare issued a positive coverage decision for GeneSight.,2019-08-01 09:45:00-04:00,MYGN,positive
877849.0,Myriad Genetics 8-K Shows UnitedHealthcare Issued A Positive Coverage Decision For Pharmacogenetic Testing For Mutli-Gene Panels Including Co.'s GeneSight Psychotropic Test,2019-08-01 09:44:00-04:00,MYGN,positive
877850.0,42 Stocks Moving In Monday's Mid-Day Session,2019-07-29 12:30:00-04:00,MYGN,neutral
877851.0,"Benzinga's Top Upgrades, Downgrades For July 29, 2019",2019-07-29 09:55:00-04:00,MYGN,positive
877852.0,Myriad Genetics shares are trading lower after Needham downgraded the company from Strong Buy to Hold.,2019-07-29 09:41:00-04:00,MYGN,positive
877853.0,Needham Downgrades Myriad Genetics to Hold,2019-07-29 07:24:00-04:00,MYGN,neutral
877854.0,Myriad Genetics shares are trading higher after the company resolved a complaint tied to Medicare billing for the Company's hereditary cancer testing for $9.1 million.,2019-07-19 15:14:00-04:00,MYGN,negative
877855.0,Myriad Genetics Says Has Resolved Complaint Filed By Qui Tam Realtor In 2017,2019-07-19 15:12:00-04:00,MYGN,negative
877856.0,Nearly 500 Kroger Pharmacies To Participate In GeneSight Program To Pilot Myriad Genetics' GeneSight Test,2019-07-10 08:13:00-04:00,MYGN,neutral
877857.0,"Benzinga's Top Upgrades, Downgrades For July 9, 2019",2019-07-09 09:02:00-04:00,MYGN,positive
877858.0,Cowen & Co. Downgrades Myriad Genetics to Market Perform,2019-07-09 06:51:00-04:00,MYGN,neutral
877859.0,Myriad Genetics Highlights Publication Of Results From Study Showing Prolaris Test Can Accurately Predict 10-Year Risk Of Metastases In Men Newly Diagnosed With Localized Prostate Cancer,2019-06-27 07:31:00-04:00,MYGN,negative
877860.0,54 Biggest Movers From Yesterday,2019-06-27 04:54:00-04:00,MYGN,neutral
877861.0,Myriad Genetics Option Alert: Jul 19 $26 Calls Sweep (2) near the Ask: 500 @ $1.25 vs 1890 OI; Earnings 8/20 After Close [est] Ref=$24.625,2019-06-26 15:50:00-04:00,MYGN,positive
877862.0,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart",2019-06-26 07:19:00-04:00,MYGN,neutral
877863.0,"The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership",2019-06-25 07:15:00-04:00,MYGN,neutral
877864.0,Pioneering genetic-testing company Myriad's biggest up-and-coming product could be at risk after scientists raised major,2019-06-21 15:16:00-04:00,MYGN,negative
877865.0,"Myriad Genetics' Labs Unit Reports Japanese Ministry Of Health, Labour, Welfare Granted Second Manufacturing, Marketing Approval For BRACAnalysis Diagnostic System As Companion With Lynparza",2019-06-19 07:10:00-04:00,MYGN,positive
877866.0,Myriad Genetics Option Alert: Jul 19 $26 Calls Sweep (23) near the Ask: 760 @ $0.9 vs 851 OI; Ref=$24.235,2019-06-12 11:11:00-04:00,MYGN,positive
877867.0,Myriad Genetics Announces New Results from Two Large Studies of Its myRisk Hereditary Cancer Test at American Society of Clinical Oncology,2019-06-03 07:09:00-04:00,MYGN,negative
877868.0,Myriad Genetics Announces BRACAnalysis CDx Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza at #ASCO19,2019-06-02 10:14:00-04:00,MYGN,negative
877869.0,"The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation",2019-05-29 07:38:00-04:00,MYGN,neutral
877870.0,"The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice",2019-05-24 07:44:00-04:00,MYGN,neutral
877871.0,"The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut",2019-05-23 07:37:00-04:00,MYGN,neutral
877872.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,MYGN,negative
877873.0,Myriad Genetics Highlights EndoPredict Test Identifies Women With Early-stage Breast Cancer Who Can Safely Forgo Extended Endocrine Therapy 5 Years After Diagnosis,2019-05-09 07:22:00-04:00,MYGN,negative
877874.0,Myriad Genetics Highlights Publication Of Data From Its EndoPredict Study In Clinical Cancer Research Journal,2019-05-09 07:22:00-04:00,MYGN,negative
877875.0,95 Biggest Movers From Yesterday,2019-05-09 05:01:00-04:00,MYGN,neutral
877876.0,75 Stocks Moving In Wednesday's Mid-Day Session,2019-05-08 12:24:00-04:00,MYGN,neutral
877877.0,Myriad Genetics shares are trading lower after the company reported worse-than-expected Q3 sales results; the company also provided Q4 and FY19 sales guidance below analyst estimates.,2019-05-08 10:32:00-04:00,MYGN,neutral
877878.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,MYGN,negative
877879.0,"Myriad Genetics Sees Q4 Adj. EPS $0.48 vs $0.48 Estimate, Sales $220M vs $225.3M Est.; FY19 Adj. EPS $1.74 vs $1.71 Est., Sales $856M vs $861.4M Est.",2019-05-07 16:19:00-04:00,MYGN,neutral
877880.0,"Myriad Genetics Q3 Adj. EPS $0.46 Beats $0.42 Estimate, Sales $216.6M Miss $217.46M Estimate",2019-05-07 16:18:00-04:00,MYGN,negative
877881.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,MYGN,neutral
877882.0,"Shares of companies in the diagnostics and research space are trading higher in sympathy with Bruker, which reported better-than-expected Q1 EPS and sales results.",2019-05-03 13:21:00-04:00,MYGN,positive
877883.0,Myriad to Present Multiple Women's Health Studies At 2019 American College Of Obstetricians And Gynecologists Annual Meeting,2019-04-23 07:10:00-04:00,MYGN,neutral
877884.0,26 Stocks Moving In Wednesday's Pre-Market Session,2019-04-10 08:05:00-04:00,MYGN,neutral
877885.0,Myriad Genetics Submits the First Module of the Premarket Approval Application to the FDA for its myChoice HRD CDx Test,2019-04-09 07:06:00-04:00,MYGN,positive
877886.0,"Myriad Genetics, AstraZeneca, Merck Report Expansion Of Companion Diagnostic Partnership",2019-04-04 07:18:00-04:00,MYGN,neutral
877887.0,Myriad Genetics shares are trading higher after the company reported the myPath Melanoma test received medicare coverage.,2019-03-14 10:09:00-04:00,MYGN,positive
877888.0,Myriad Genetics Reports myPath Test Received Medicare Coverage,2019-03-14 08:27:00-04:00,MYGN,neutral
877889.0,Myriad Genetics Option Alert: May 17 $32 Calls Sweep (3) near the Ask: 5000 @ $1.75 vs 42 OI; Earnings 5/7 Before Open [est] Ref=$29.1,2019-03-11 10:47:00-04:00,MYGN,positive
877890.0,Myriad Highlights Publication Of Expanded Carrier Screen Study In Genetics In Medicine,2019-03-06 07:13:00-05:00,MYGN,neutral
877891.0,UPDATE: Myriad Genetics Says Will Seek FDA Approval Of BRACAnalysis CDx As Companion Diagnostic For Olaparib In Patient Population,2019-02-26 13:12:00-05:00,MYGN,positive
877892.0,Myriad Genetics Reports BRACAnalysis CDx Test Successfully Identified Patients With Metastatic Pancreatic Cancer Who Benefited From Treatment With Olaparib,2019-02-26 13:11:00-05:00,MYGN,negative
877893.0,Myriad Genetics Announces Its Prequel Prenatal Screen Has Expanded To Include All 23 Chromosome Pairs,2019-02-11 07:13:00-05:00,MYGN,neutral
877894.0,"Myriad Genetics shares are trading higher after the company reported Q2 sales of $216.8M, beating the $216.73M estimate. The company also issued Q3 EPS and sales guidance in the higher range of analyst estimates.",2019-02-06 13:10:00-05:00,MYGN,negative
877895.0,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering",2019-02-06 08:23:00-05:00,MYGN,neutral
877896.0,"Myriad Genetics Sees Q3 Adj. EPS $0.42-$0.44 vs $0.42 Est., Sales $216M-$218M vs $215.9M Est., Sees FY19 Adj. EPS $1.70-$1.75 vs $1.74 Est., Sales $855M-$865M vs $863.69M Est.",2019-02-05 16:15:00-05:00,MYGN,neutral
877897.0,"Myriad Genetics Q2 EPS $0.38 Misses $0.41 Estimate, Sales $216.8M Beat $216.73M Estimate",2019-02-05 16:09:00-05:00,MYGN,negative
877898.0,"Earnings Scheduled For February 5, 2019",2019-02-05 04:01:00-05:00,MYGN,neutral
877899.0,CORRECTION: Recent Comments On Myriad Genetics Comes From SeekingAlpha Post From The Capitolist 'Myriad: FOIAs Reveal 50% Downside As Majority Of EBITDA Potentially At Risk From Reduced Reimbursement Rates',2019-01-16 10:55:00-05:00,MYGN,negative
877900.0,Myriad Genetics Shares Fall ~1% Over Last Min.; Traders Attributing To Comments From The Capitolist SeekingAlpha Contributor 'Myriad: FOIAs Reveal 50% Downside As Majority Of EBITDA Potentially At Risk From Reduced Reimbursement Rates',2019-01-16 10:52:00-05:00,MYGN,negative
877901.0,24 Stocks Moving In Tuesday's Pre-Market Session,2019-01-08 08:19:00-05:00,MYGN,neutral
877902.0,65 Biggest Movers From Yesterday,2019-01-08 05:16:00-05:00,MYGN,neutral
877903.0,"Myriad Genetics shares are trading lower after a report, from the Southern Investigative Reporting Foundation, stated that Myriad Genetics has great difficulties telling the truth.",2019-01-07 10:30:00-05:00,MYGN,positive
877904.0,'Myriad Genetics: This Company Has Great Difficulties Telling the Truth' -Report From Southern Investigative Reporting Foundation,2019-01-07 09:50:00-05:00,MYGN,positive
877905.0,"Myriad Genetics Highlights GUIDED Study Published In 'Journal Of Psychiatric Research,' Showed 'individuals in the GeneSight cohort had 50% higher rate of remission, 30% higher rate of response, 11% great improvement in symptoms...'",2019-01-04 10:06:00-05:00,MYGN,positive
877906.0,Cowen & Co. Upgrades Myriad Genetics to Outperform,2019-01-04 06:56:00-05:00,MYGN,neutral
877907.0,Myriad Genetics Announces FDA Approval Of BRACAnalysis CDxAs A Companion Diagnostic For AstraZeneca's Lynparza For Ovarian Cancer,2018-12-19 13:11:00-05:00,MYGN,negative
877908.0,Myriad Genetics Reports UK's National Institute For Health And Care Excellence Included Co.'s EndoPredict In Recommendations For Guiding Adjuvant Chemotherapy Decisions,2018-12-19 07:09:00-05:00,MYGN,positive
877909.0,31 Stocks Moving In Monday's Pre-Market Session,2018-12-10 08:16:00-05:00,MYGN,neutral
877910.0,Myriad Genetics Issues Release Highlighting Presentation Of New Data for Its EndoPredict® Breast Cancer Test At San Antonio Breast Cancer Symposium,2018-12-07 08:34:00-05:00,MYGN,negative
877911.0,"Benzinga's Top Upgrades, Downgrades For November 30, 2018",2018-11-30 09:15:00-05:00,MYGN,positive
877912.0,"Goldman Sachs Upgrades Myriad Genetics to Neutral, Raises Price Target to $32",2018-11-30 06:54:00-05:00,MYGN,neutral
877913.0,Myriad Announces $50M Buyback,2018-11-19 07:06:00-05:00,MYGN,neutral
877914.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,MYGN,negative
877915.0,"Myriad Genetics Reaffirms FY19 Adj. EPS Guidance $1.70-$1.75 vs $1.72 Estimate, Sales Cut From $880M-$890M To $855M-$865M vs $888M Est.",2018-11-06 16:25:00-05:00,MYGN,negative
877916.0,"Myriad Genetics, Inc. Q1 EPS $0.43 Beats $0.30 Estimate, Sales $202.3M Miss $202.46M Estimate",2018-11-06 16:23:00-05:00,MYGN,negative
877917.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,MYGN,positive
877918.0,"Earnings Scheduled For November 6, 2018",2018-11-06 05:31:00-05:00,MYGN,neutral
877919.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,MYGN,neutral
877920.0,76 Biggest Movers From Yesterday,2018-11-02 06:12:00-04:00,MYGN,neutral
877921.0,56 Stocks Moving In Thursday's Mid-Day Session,2018-11-01 12:59:00-04:00,MYGN,neutral
877922.0,"Hearing Morgan Stanley Out Defending Myriad Genetics; Firm Says Stock Move Today Reflects 'Confusion On The Regulatory Backdrop For Enetic Tests', Unconfirmed",2018-11-01 12:37:00-04:00,MYGN,negative
877923.0,Myriad Genetics Reports Clinical Study Using Foresight Carrier Screen Published In 'Genetics In Medicine',2018-10-23 07:14:00-04:00,MYGN,neutral
877924.0,Myriad Genetics Reports Its BRACAnalysis CDx Test Identified Patients With Newly-Diagnosed Advanced Ovarian Cancer Who May Benefit From Maintenance Treatment With Lynparza,2018-10-22 07:07:00-04:00,MYGN,negative
877925.0,Myriad Receives FDA Approval Of BRACAnalysis CDx As Companion Diagnostic For Pfizer's TALZENNA,2018-10-16 12:17:00-04:00,MYGN,positive
877926.0,41 Stocks Moving In Wednesday's Mid-Day Session,2018-10-10 12:54:00-04:00,MYGN,neutral
877927.0,"Benzinga's Top Upgrades, Downgrades For October 10, 2018",2018-10-10 08:58:00-04:00,MYGN,positive
877928.0,30 Stocks Moving In Wednesday's Pre-Market Session,2018-10-10 08:02:00-04:00,MYGN,neutral
877929.0,Myriad Announces New Laboratory Agreement with Pfizer; Myriad Will Provide BRACAnalysis CDx Testing In Phase 2 Study Evaluating Pfizer's Talazoparib,2018-10-10 07:07:00-04:00,MYGN,positive
877930.0,"PiperJaffray Upgrades Myriad Genetics to Overweight, Raises Price Target to $53",2018-10-10 06:47:00-04:00,MYGN,negative
877931.0,"UPDATE: Myriad Genetics Says GeneSight Study Showed 'use of CPGx yielded reduced spending for a commercial health plan across the patient population with psychiatric disorders, as well as among high-cost subpopulations'",2018-09-26 12:45:00-04:00,MYGN,positive
877932.0,Myriad Genetics Issues Press Release Highlighting Health Economic Study To Evaluate Financial Impact Of GeneSight CPGx Test On Major Commercial Health Plans In 'Personalized Medicine' Journal,2018-09-26 12:45:00-04:00,MYGN,neutral
877933.0,54 Biggest Movers From Yesterday,2018-09-06 05:13:00-04:00,MYGN,neutral
877934.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-09-05 12:40:00-04:00,MYGN,neutral
877935.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,MYGN,neutral
877936.0,10 Biggest Price Target Changes For Wednesday,2018-09-05 09:38:00-04:00,MYGN,neutral
877937.0,"Benzinga's Top Upgrades, Downgrades For September 5, 2018",2018-09-05 09:10:00-04:00,MYGN,positive
877938.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,MYGN,positive
877939.0,"Barclays Downgrades Myriad Genetics to Underweight, Lowers Price Target to $30",2018-09-05 06:07:00-04:00,MYGN,negative
877940.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,MYGN,neutral
877941.0,"Stocks Which Set New 52-Week High Yesterday, August 29th",2018-08-30 11:47:00-04:00,MYGN,neutral
877942.0,"Stocks Which Set New 52-Week High Yesterday, August 28th",2018-08-29 11:13:00-04:00,MYGN,neutral
877943.0,10 Biggest Price Target Changes For Tuesday,2018-08-28 09:48:00-04:00,MYGN,neutral
877944.0,"Leerink Swann Maintains Market Perform on Myriad Genetics, Raises Price Target to $49",2018-08-28 07:25:00-04:00,MYGN,neutral
877945.0,"Stocks Which Set New 52-Week High Yesterday, August 23rd",2018-08-24 09:11:00-04:00,MYGN,neutral
877946.0,"The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict",2018-08-24 08:47:00-04:00,MYGN,positive
877947.0,"Stocks Which Set New 52-Week High Yesterday, August 22nd",2018-08-23 10:51:00-04:00,MYGN,neutral
877948.0,"The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero",2018-08-23 08:23:00-04:00,MYGN,negative
877949.0,50 Biggest Movers From Yesterday,2018-08-23 05:10:00-04:00,MYGN,neutral
877950.0,35 Stocks Moving In Wednesday's Mid-Day Session,2018-08-22 12:23:00-04:00,MYGN,neutral
877951.0,Myriad Genetics shares are trading up 7.1% after the company late Tuesday reported a Q4 earnings beat and issued strong Q1 and 2019 sales guidance.,2018-08-22 09:46:00-04:00,MYGN,positive
877952.0,"Barclays Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $38",2018-08-22 08:48:00-04:00,MYGN,neutral
877953.0,"The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin",2018-08-22 08:20:00-04:00,MYGN,negative
877954.0,24 Stocks Moving In Wednesday's Pre-Market Session,2018-08-22 08:00:00-04:00,MYGN,neutral
877955.0,Myriad Genetics shares are up 7.4% after hours following a Q4 earnings beat; The company also issued strong sales guidance for both Q1 and 2019.,2018-08-21 16:24:00-04:00,MYGN,positive
877956.0,"Myriad Genetics Sees FY19 Adj. EPS $1.70-$1.75 vs $1.40 Est., Sales $880M-$890M vs $781.46M Est.",2018-08-21 16:08:00-04:00,MYGN,neutral
877957.0,"Myriad Genetics Sees Q1 Adj. EPS $0.28-$0.30 vs $0.31 Est., Sales $200M-$202M vs $191.64M Est.",2018-08-21 16:07:00-04:00,MYGN,neutral
877958.0,"Myriad Genetics Q4 Adj. EPS $0.38 Beats $0.33 Estimate, Sales $200.9M Beat $195.76M Estimate",2018-08-21 16:06:00-04:00,MYGN,neutral
877959.0,"The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows",2018-08-21 08:40:00-04:00,MYGN,positive
877960.0,"Earnings Scheduled For August 21, 2018",2018-08-21 04:07:00-04:00,MYGN,neutral
877961.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Earnings",2018-08-19 12:00:00-04:00,MYGN,neutral
877962.0,"Earnings Scheduled For August 14, 2018",2018-08-14 04:32:00-04:00,MYGN,neutral
877963.0,"Myriad Reschedules Release of Fiscal Fourth-Quarter 2018 Financial Results, Company Reaffirms Fiscal 2018 Guidance and Will Now Release Results on August 21, 2018",2018-08-13 07:10:00-04:00,MYGN,neutral
877964.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-08-12 16:52:00-04:00,MYGN,neutral
877965.0,"Stocks Which Set New 52-Week High Yesterday, August 7th",2018-08-08 11:01:00-04:00,MYGN,neutral
877966.0,"Stocks Which Set New 52-Week High Yesterday, August 6th",2018-08-07 11:27:00-04:00,MYGN,neutral
877967.0,"Stocks Which Set New 52-Week High Yesterday, August 1st",2018-08-02 10:56:00-04:00,MYGN,neutral
877968.0,Myriad Genetics Filing Shows Registration For ~2.99M Share Common Stock Offering Via Selling Shareholders,2018-08-01 16:25:00-04:00,MYGN,positive
877969.0,Seeing Notable Block Trade In Myriad Genetics; 1M Shares at $42.50,2018-07-26 14:13:00-04:00,MYGN,negative
877970.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,MYGN,neutral
877971.0,"Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial",2018-07-12 08:37:00-04:00,MYGN,neutral
877972.0,44 Biggest Movers From Yesterday,2018-07-12 04:00:00-04:00,MYGN,neutral
877973.0,Mid-Afternoon Market Update: Dow Down Over 200 Points; Achieve Life Sciences Shares Spike Higher,2018-07-11 14:32:00-04:00,MYGN,positive
877974.0,4 Reasons Why Morgan Stanley Is Bullish On Myriad Genetics,2018-07-11 14:15:00-04:00,MYGN,neutral
877975.0,Mid-Day Market Update: Crude Oil Down Over 2%; Simulations Plus Shares Plunge,2018-07-11 12:50:00-04:00,MYGN,negative
877976.0,38 Stocks Moving In Wednesday's Mid-Day Session,2018-07-11 12:35:00-04:00,MYGN,neutral
877977.0,Mid-Morning Market Update: Markets Open Lower; Fastenal Profit Tops Views,2018-07-11 10:14:00-04:00,MYGN,positive
877978.0,8 Biggest Price Target Changes For Wednesday,2018-07-11 09:51:00-04:00,MYGN,neutral
877979.0,"Benzinga's Top Upgrades, Downgrades For July 11, 2018",2018-07-11 09:05:00-04:00,MYGN,positive
877980.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-07-11 08:05:00-04:00,MYGN,neutral
877981.0,"Morgan Stanley Upgrades Myriad Genetics to Overweight, Raises Price Target to $55",2018-07-11 07:26:00-04:00,MYGN,negative
877982.0,Top-Five National Payer Issues Positive Coverage Decision For Myriad's Prolaris Test For Prostate Cancer,2018-06-21 07:17:00-04:00,MYGN,negative
877983.0,Myriad's BRACAnalysis CDx Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer,2018-06-18 07:23:00-04:00,MYGN,negative
877984.0,28 Stocks Moving In Monday's Pre-Market Session,2018-06-04 08:11:00-04:00,MYGN,neutral
877985.0,Myriad Genetics Shares Up 6.0% After Co. Reported It Would Announce Results From Second Major Clinical Validation Study Of riskScore Test At ASCO '18,2018-06-01 12:11:00-04:00,MYGN,positive
877986.0,Myriad Genetics Highlights Will Offer Results From Second Major Clinical Validation Study Of riskScore Test At ASCO '18,2018-06-01 07:09:00-04:00,MYGN,neutral
877987.0,"UPDATE: Myriad Genetics Reports IMPACT Study Showed When Clinicians Used GeneSight Test Results To Guide Medication Selection, Patients Saw 28% Mean Reduction In Symptoms",2018-05-31 07:19:00-04:00,MYGN,neutral
877988.0,Myriad Genetics Reports Results From IMPACT Study Of GeneSight By Wholly-Owned Subsidiary Assurex Health Will Be Highlighted At ASCP Annual Meeting,2018-05-31 07:18:00-04:00,MYGN,neutral
877989.0,A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street,2018-05-29 06:57:00-04:00,MYGN,negative
877990.0,"Myriad Genetics Signs Definitive Agreement to Acquire Counsyl for $375M in Cash, Stock",2018-05-29 04:27:00-04:00,MYGN,positive
877991.0,Myriad Genetics Announces 7 New Payer Coverage Decisions for Prolaris,2018-05-23 16:10:00-04:00,MYGN,neutral
877992.0,53 Biggest Movers From Yesterday,2018-05-09 05:37:00-04:00,MYGN,neutral
877993.0,Myriad Genetics Spikes On Better-Than-Expected Q3 Print,2018-05-08 14:10:00-04:00,MYGN,neutral
877994.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,MYGN,neutral
877995.0,Myriad Genetics Raises FY18 Adj. EPS Guidance From $1.11-$1.16 to $1.19-$1.21 vs $1.15 Est.,2018-05-08 06:39:00-04:00,MYGN,neutral
877996.0,"Myriad Genetics Q3 EPS $0.31 Beats $0.27 Estimate, Sales $193.5M Beat $188.22M Estimate",2018-05-08 06:37:00-04:00,MYGN,neutral
877997.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-02 10:04:00-04:00,MYGN,neutral
877998.0,Myriad Receives Pre-Market Approval for its BRACAnalysis Diagnostic System in Japan,2018-04-02 07:07:00-04:00,MYGN,positive
877999.0,"Benzinga's Top Upgrades, Downgrades For March 21, 2018",2018-03-21 09:31:00-04:00,MYGN,positive
878000.0,"The Market In 5 Minutes: China, Facebook, Nordstrom And More",2018-03-21 09:00:00-04:00,MYGN,neutral
878001.0,Morgan Stanley Upgrades Myriad Genetics to Equal-Weight,2018-03-21 07:07:00-04:00,MYGN,neutral
878002.0,45 Biggest Movers From Yesterday,2018-03-14 04:55:00-04:00,MYGN,neutral
878003.0,35 Stocks Moving In Tuesday's Mid-Day Session,2018-03-13 12:28:00-04:00,MYGN,neutral
878004.0,STAT News Publishes 'FDA approves first direct-to-consumer test for breast cancer risk',2018-03-06 11:27:00-05:00,MYGN,negative
878005.0,Myriad Genetics PR Highlights JAMA Oncology Publication That Shows EndoPredict (EPClin) Significantly Outperforms Oncotype DX Recurrence Score in Early-Stage Breast Cancer,2018-02-15 11:15:00-05:00,MYGN,negative
878006.0,"Myriad Genetics Reports Q2 Adj. EPS $0.31 vs $0.24 Est., Sales $194M vs $188.8M Est.",2018-02-06 16:06:00-05:00,MYGN,neutral
878007.0,A Preview Of Myriad Genetics' Q2 Earnings,2018-02-06 12:30:00-05:00,MYGN,neutral
878008.0,"Jim Cramer Advises His Viewers On Align Technology, Kennametal And More",2018-02-02 07:34:00-05:00,MYGN,neutral
878009.0,Goldman Sachs Models 22% Downside To Myriad Genetics,2018-01-29 18:01:00-05:00,MYGN,negative
878010.0,"Goldman Sachs Initiates Coverage On Myriad Genetics with Sell Rating, Announces $32.00 Price Target",2018-01-29 09:10:00-05:00,MYGN,neutral
878011.0,28 Stocks Moving In Monday's Pre-Market Session,2018-01-29 08:00:00-05:00,MYGN,neutral
878012.0,Myriad Receives FDA Approval of BRACAnalysis CDx as Companion Diagnostic for Lynparza in Patients with Metastatic Breast Cancer GLN,2018-01-12 11:17:00-05:00,MYGN,negative
878013.0,"Benzinga's Top Upgrades, Downgrades For January 5, 2018",2018-01-05 09:11:00-05:00,MYGN,positive
878014.0,"BTIG Research Initiates Coverage On Myriad Genetics with Buy Rating, Announces $41.00 Price Target",2018-01-05 07:46:00-05:00,MYGN,neutral
878015.0,Myriad Genetics Announces AstraZeneca to Use the Company's myChoice HRD Plus in an Exploratory Cancer Analysis,2018-01-03 07:06:00-05:00,MYGN,negative
878016.0,Stephens' Analysts Present Their Best Ideas For 2018,2018-01-02 14:19:00-05:00,MYGN,positive
878017.0,Myriad Genetics Reports BRACAnalysis CDx Test Effectively Identified Metastatic Breast Cancer Patients With Improved Outcomes From Pfizer's Talazoparib,2017-12-12 07:12:00-05:00,MYGN,positive
878018.0,Myriad Genetics' Latest Alliance To Boost GeneSight Reach,2017-11-15 12:44:00-05:00,MYGN,positive
878019.0,"Myriad Genetics Sees FY18 Adj. EPS $1-$1.05, Sales $750M-$770M",2017-11-07 16:38:00-05:00,MYGN,neutral
878020.0,"Myriad Genetics Sees Q2 Adj. EPS $0.22-$0.24, Sales $187M-$189M",2017-11-07 16:38:00-05:00,MYGN,neutral
878021.0,"Myriad Genetics Reports Q1 Adj. EPS $0.26 vs. $0.21 Est., Sales $190.2M vs. $183.38M Est.",2017-11-07 16:36:00-05:00,MYGN,neutral
878022.0,Myriad Genetics Reports Collaboration With CareFirst BlueCross BlueShield On Coverage With Evidence Development Study For Vectra DA Test,2017-11-06 07:08:00-05:00,MYGN,neutral
878023.0,UPDATE: Myriad Says Patients Receiving GeneSight Test Achieved Clinically Meaningful and Statistically Significant Improvement in Remission Rates and Response Rates at Weeks vs Treatment-as-usual Group.,2017-11-02 07:15:00-04:00,MYGN,positive
878024.0,Myriad Announces GeneSight® Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder,2017-11-02 07:13:00-04:00,MYGN,negative
878025.0,Myriad Submits BRACAnalysis CDx Application for Regulatory Approval in Japan for HER2- Metastatic Breast Cancer,2017-10-24 07:23:00-04:00,MYGN,negative
878026.0,GeneSight Announces 'Positive' for GeneSight in Patients with Generalized Anxiety Disorder,2017-10-19 07:10:00-04:00,MYGN,negative
878027.0,Myriad Genetics Reports BRACAnalysis CDx Supplementary PMA Accepted By FDA For Review As Companion Diagnostic For Lynparza In Metastatic Breast Cancer,2017-10-18 07:04:00-04:00,MYGN,negative
878028.0,"Benzinga's Top Upgrades, Downgrades For October 2, 2017",2017-10-02 09:25:00-04:00,MYGN,positive
878029.0,"Leerink Swann Initiates Coverage On Myriad Genetics with Market Perform Rating, Announces $31.00 Price Target",2017-10-02 07:39:00-04:00,MYGN,neutral
878030.0,Myriad Genetics Announces 'Positive' Supporting New riskScore Test,2017-09-15 07:05:00-04:00,MYGN,positive
878031.0,Myriad Genetics Announces Launch Of riskScore Test,2017-09-05 16:40:00-04:00,MYGN,neutral
878032.0,15 Biggest Mid-Day Gainers For Friday,2017-08-18 12:37:00-04:00,MYGN,neutral
878033.0,Increased Confidence Earns Myriad Genetics An Upgrade,2017-08-18 10:28:00-04:00,MYGN,positive
878034.0,"Benzinga's Top Upgrades, Downgrades For August 18, 2017",2017-08-18 09:19:00-04:00,MYGN,positive
878035.0,A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Consumer Sentiment Report,2017-08-18 07:13:00-04:00,MYGN,neutral
878036.0,Deutsche Bank Upgrades Myriad Genetics to Hold,2017-08-18 06:34:00-04:00,MYGN,neutral
878037.0,Myriad Genetics Announces Positive Coverage Decisions From Medicare And Anthem,2017-08-17 16:16:00-04:00,MYGN,positive
878038.0,"Myriad Genetics Sees FY18 Adj. EPS $1-$1.05 vs $1.08 Est., Sales $750M-$770M vs $789.1M Est.",2017-08-08 16:17:00-04:00,MYGN,neutral
878039.0,"Myriad Genetics Sees Q1 Adj. EPS $0.19-$0.21 vs $0.24 Est., Sales $181M-$183M vs $191.9M Est.",2017-08-08 16:17:00-04:00,MYGN,neutral
878040.0,"Myriad Genetics Reports Q4 Adj. EPS $0.30 vs $0.26 Est., Sales $200.5M vs $193.7M Est.",2017-08-08 16:16:00-04:00,MYGN,neutral
878041.0,Watch These 8 Huge Put Purchases In Tuesday Trade,2017-08-01 04:22:00-04:00,MYGN,positive
878042.0,Benzinga's Option Alert Recap From July 31,2017-07-31 16:05:00-04:00,MYGN,positive
878043.0,Myriad Genetics Option Alert: Aug 18 $21 Puts at the Bid: 6846 @ $0.201 vs 218 OI; Ref=$24.27 Signals,2017-07-31 10:28:00-04:00,MYGN,positive
878044.0,JPMorgan Checks In On Myriad Genetics Following 30% Rally,2017-06-29 15:06:00-04:00,MYGN,neutral
878046.0,"8-K From Myriad Genetics Shows Co. Agreed On New Long-Term Relationship With UnitedHealthcare Which Established Pricing For GeneSight, Polaris, Vectra DA, EndoPredict",2017-06-21 09:13:00-04:00,MYGN,positive
878047.0,Watch These 8 Huge Call Purchases In Tuesday Trade,2017-06-06 05:00:00-04:00,MYGN,positive
878048.0,Option Alert: Myriad Gen Jun 22.0 Calls: 2674 @  ASK  $0.20: 3504 traded vs 568 OI:  Earnings 8/8 After Close (est)  $20.90 Ref,2017-06-05 11:33:00-04:00,MYGN,positive
878049.0,Myriad Announces BRACAnalysis CDx Test Identified Patients with Metastatic Breast Cancer Who Benefited from Treatment with Olaparib in Phase 3 OlympiAD Study,2017-06-04 08:15:00-04:00,MYGN,negative
878050.0,Myriad Genetics Issues Release Highlighting 17 Added Health Insurance Plans Now Covering EndoPredict,2017-06-02 16:21:00-04:00,MYGN,neutral
878051.0,Myriad Genetics Gives update on myRisk Study,2017-06-02 07:09:00-04:00,MYGN,neutral
878052.0,Option Alert: Myriad Gen Jun 21 Call; 5111 @Bid @$0.20; Ref=$20.18,2017-05-30 15:49:00-04:00,MYGN,positive
878053.0,Myriad Genetics Announced New Data Demonstrating Utility of Prolaris Test to Predict 10-Year Risk of Metastases in Men Treated for Prostate Cancer,2017-05-12 07:12:00-04:00,MYGN,negative
878054.0,Benzinga's Option Alert Recap From May 8,2017-05-08 16:35:00-04:00,MYGN,positive
878055.0,"Option Alert: Myriad Genetics Jun. $21 Puts: Volume of 2,500 at $0.475/Contract",2017-05-08 10:16:00-04:00,MYGN,positive
878056.0,20 Biggest Mid-Day Gainers For Wednesday,2017-05-03 12:37:00-04:00,MYGN,neutral
878057.0,"Myriad Genetics Reports Q3 Adj. EPS $0.27 vs $0.23 Est., Sales $196.9M vs $189.1M Est.",2017-05-02 16:07:00-04:00,MYGN,neutral
878058.0,Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx Test to Identify Patients with Germline BRCA Mutations for Rubraca,2017-04-27 08:22:00-04:00,MYGN,positive
878059.0,"Myriad Genetics, BeiGene Sign Agreement To Develop Diagnostics For Use With Beigene's BGB-290",2017-04-06 07:06:00-04:00,MYGN,positive
878060.0,"Myriad Genetics Says Pivotal Results From 2  Studies On myPath Melanoma Test, Says Company Will Seek Reimbursement From Both Medicare and Private Payers",2017-04-05 07:07:00-04:00,MYGN,neutral
878061.0,"Tesaro Announces Expanded Development Program For Cancer Drug Niraparib, Stock Spikes Higher",2017-03-27 16:32:00-04:00,MYGN,negative
878062.0,Myriad Genetics Selling Off On TESARO Broad Label Details,2017-03-27 15:38:00-04:00,MYGN,neutral
878063.0,Myriad Genetics Sells off  to Low of $18.75 on Volume,2017-03-27 15:38:00-04:00,MYGN,negative
878064.0,Myriad Genetics Launches the EndoPredict Test in the United States,2017-03-13 07:14:00-04:00,MYGN,positive
878065.0,13G Filing Shows D.E. Shaw & Co Reporting 5% Stake In Myriad Genetics,2017-03-06 16:04:00-05:00,MYGN,neutral
878066.0,"MYRIAD GENETICS INC: HENDERSON JOHN T (Director) Buys 6,000 @ Avg Price: $18.66 (Form4)",2017-02-23 11:22:00-05:00,MYGN,neutral
878067.0,Myriad Genetics Pops to High on Volume,2017-02-23 11:21:00-05:00,MYGN,neutral
878068.0,Myriad Genetics Reports Prolaris Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate Cancer,2017-02-17 07:14:00-05:00,MYGN,negative
878069.0,20 Biggest Mid-Day Gainers For Wednesday,2017-02-08 12:34:00-05:00,MYGN,neutral
878070.0,"Benzinga's Top Upgrades, Downgrades For February 8, 2017",2017-02-08 09:51:00-05:00,MYGN,positive
878071.0,Myriad Genetics' Sell Thesis Is 'Largely Played Out',2017-02-08 09:33:00-05:00,MYGN,positive
878072.0,"The Market In 5 Minutes: Disney, Gilead Investors Not Too Pleased",2017-02-08 09:03:00-05:00,MYGN,negative
878073.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-02-08 08:28:00-05:00,MYGN,neutral
878074.0,Ladenburg Thalmann Upgrades Myriad Genetics To Neutral,2017-02-08 06:50:00-05:00,MYGN,neutral
878075.0,"Myriad Genetics Sees Q3 Adj. EPS $0.23-$0.25 vs $0.25 Est., Sales $188M-$190M vs $190.2M Est.",2017-02-07 16:15:00-05:00,MYGN,neutral
878076.0,"UPDATE: Myriad Genetics Narrows FY17 Adj. EPS Outlook from $1-$1.10 to $1-$1.05 vs $1.08 Est., Sales from $740M-$760M to $745M-$755M vs $774.3M Est.",2017-02-07 16:14:00-05:00,MYGN,neutral
878077.0,"Myriad Genetics Narrows, Lowers Top End of FY17 Outlook",2017-02-07 16:14:00-05:00,MYGN,positive
878078.0,"Myriad Genetics Reports Q2 Adj. EPS $0.26 vs $0.24 Est., Sales $196.5M vs $189.7M Est.",2017-02-07 16:13:00-05:00,MYGN,neutral
878079.0,Watch These 8 Huge Put Purchases In Thursday Trade,2017-02-02 04:25:00-05:00,MYGN,positive
878080.0,Benzinga's Option Alert Recap From February 1,2017-02-01 17:09:00-05:00,MYGN,positive
878081.0,Option Alert: Myriad Genetics May 13.0 Puts Sweep: 582 @  ASK  $0.55: 582 traded vs 175 OI:  Earnings 2/7 After Close  $16.14 Ref,2017-02-01 14:57:00-05:00,MYGN,positive
878082.0,Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector,2017-01-18 12:29:00-05:00,MYGN,positive
878083.0,"Deutsche Bank Initiates Coverage On Myriad Genetics At Sell, Announces $15 Price Target",2017-01-18 08:44:00-05:00,MYGN,neutral
878084.0,Myriad Genetics Gets Positive Test Coverage Decisions From Blue Cross Blue Shield Affiliate Plans for EndoPredict,2017-01-06 07:08:00-05:00,MYGN,positive
878085.0,Medicare Decisions For Myriad Present A Mixed Bag,2016-12-27 10:07:00-05:00,MYGN,neutral
878086.0,Myriad Genetics Shares Down 4.71%; Hearing PiperJaffray Out Questioning Whether Medicare Will Continue Coverage Of Myriad's Vectra Blood Test,2016-12-23 10:30:00-05:00,MYGN,positive
878087.0,Myriad Genetics Announces Crescendo Bioscience Reports United Rheumatology Added Vectra DA to Clinical Practice Guidelines for Adults with RA,2016-12-22 14:06:00-05:00,MYGN,positive
878088.0,10 Stocks With Highest Close In Three Weeks,2016-12-14 04:39:00-05:00,MYGN,neutral
878089.0,Myriad Subsidiary Crescendo Bioscience Announces Four Studies with Vectra® DA Will Be Presented at the American College of Rheumatology 2016 Annual Meeting,2016-11-12 18:21:00-05:00,MYGN,neutral
878090.0,Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx,2016-11-07 07:05:00-05:00,MYGN,positive
878091.0,18 Biggest Mid-Day Losers For Wednesday,2016-11-02 13:14:00-04:00,MYGN,negative
878092.0,"Worst Performing Industries For November 2, 2016",2016-11-02 11:26:00-04:00,MYGN,negative
878093.0,Stocks Hitting 52-Week Lows,2016-11-02 10:52:00-04:00,MYGN,negative
878094.0,"Stephens & Co. Downgrades Myriad Genetics, Inc. - Common Stock to Equal-Weight",2016-11-02 09:38:00-04:00,MYGN,neutral
878095.0,"10 Stocks That Rallied Four Days, Then Sold Off Yesterday",2016-11-02 07:36:00-04:00,MYGN,neutral
878096.0,Exclusive: Myriad Genetics Discusses The Growing Market In Genetic Testing,2016-10-26 10:20:00-04:00,MYGN,positive
878097.0,Myriad Genetics Reports Formation of Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services,2016-10-21 09:31:00-04:00,MYGN,negative
878098.0,Stocks Hitting  52-Week Lows,2016-10-13 10:24:00-04:00,MYGN,negative
878099.0,Bloomberg Reporter Caroline Chen Tweets: Federal judge on Oct. 7 refused $TSRO request for restraining order on $MYGN press release on NOVA -- via @business,2016-10-11 13:17:00-04:00,MYGN,negative
878100.0,What TESARO's Phase 3 NOVA Results Mean For Myriad Genetics,2016-10-10 13:14:00-04:00,MYGN,neutral
878101.0,8 Biggest Mid-Day Losers For Monday,2016-10-10 13:01:00-04:00,MYGN,negative
878102.0,Benzinga's Top Downgrades,2016-10-10 09:19:00-04:00,MYGN,positive
878103.0,"Ladenburg Thalmann Downgrades Myriad Genetics, Inc. to Sell",2016-10-10 08:42:00-04:00,MYGN,neutral
878104.0,16 Stocks Moving In Monday's Pre-Market Session,2016-10-10 08:42:00-04:00,MYGN,neutral
878105.0,Myriad Genetics Announces myChoice HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib,2016-10-09 08:08:00-04:00,MYGN,negative
878106.0,Myriad Announces Four Poster Presentations at ESMO 2016,2016-10-07 04:57:00-04:00,MYGN,neutral
878107.0,9 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-04 09:57:00-04:00,MYGN,neutral
878108.0,"Top Performing Industries  For September 22, 2016",2016-09-22 11:32:00-04:00,MYGN,positive
878109.0,"Myriad Genetics, Inc. Ticks Lower As, FDA Recommends Against Use Of Ovarian Cancer Screening Tests",2016-09-07 15:35:00-04:00,MYGN,negative
878110.0,Myriad Genetics Falls to Low of $20.08 on Volume,2016-09-07 15:26:00-04:00,MYGN,negative
878111.0,"CEO Capone Buys 10,000 Shares Of Myriad Genetics @$21.24/Share -Form 4",2016-08-19 11:43:00-04:00,MYGN,positive
878112.0,Wednesday's Market Wrap: U.S. Stocks Trend Lower Mid-Week,2016-08-10 16:42:00-04:00,MYGN,negative
878113.0,Mid-Afternoon Market Update: Dow Falls 50 Points; Myriad Genetics Shares Decline Following Downbeat Results,2016-08-10 14:34:00-04:00,MYGN,positive
878114.0,20 Biggest Mid-Day Losers For Wednesday,2016-08-10 13:06:00-04:00,MYGN,negative
878115.0,Mid-Day Market Update: Crude Oil Down 2%; Clean Energy Fuels Shares Climb Following Upbeat Earnings,2016-08-10 12:09:00-04:00,MYGN,positive
878116.0,"Worst Performing Industries For August 10, 2016",2016-08-10 11:11:00-04:00,MYGN,negative
878117.0,Stocks Hitting 52-Week Lows,2016-08-10 10:20:00-04:00,MYGN,negative
878118.0,"Even After Dipping Under $21, Morgan Stanley Says Myriad Genetics Is Not Cheap",2016-08-10 10:07:00-04:00,MYGN,neutral
878119.0,Mid-Morning Market Update: Markets Mostly Lower; Michael Kors Issues Downbeat Guidance,2016-08-10 09:56:00-04:00,MYGN,negative
878120.0,10 Biggest Price Target Changes For Wednesday,2016-08-10 09:53:00-04:00,MYGN,neutral
878121.0,"Pre-Market Losers Aug. 10, 2016: MYGN Down 28.28%, KORS 3.91%, SPWR 28.69%, PRGO 11.58%, OA 10.62%, OHRP 9.56%",2016-08-10 09:20:00-04:00,MYGN,negative
878122.0,"Barclays Downgrades Myriad, Says Hereditary Cancer Testing Losses Came Faster Than Expected",2016-08-10 09:19:00-04:00,MYGN,negative
878123.0,Benzinga's Top Downgrades,2016-08-10 09:12:00-04:00,MYGN,positive
878124.0,Gabelli & Co. Downgrades Myriad Genetics to Hold,2016-08-10 08:28:00-04:00,MYGN,neutral
878125.0,22 Stocks Moving In Wednesday's Pre-Market Session,2016-08-10 08:25:00-04:00,MYGN,neutral
878126.0,Wells Fargo Downgrades Myriad Genetics to Market Perform,2016-08-10 07:09:00-04:00,MYGN,positive
878127.0,PiperJaffray Downgrades Myriad Genetics to Neutral,2016-08-10 06:50:00-04:00,MYGN,neutral
878128.0,"Barclays Downgrades Myriad Genetics to Equal-weight, Lowers PT to $24.00",2016-08-10 03:49:00-04:00,MYGN,negative
878129.0,"After-Hours Losers Aug. 9, 2016: SPWR Down 29%, MYGN 23%, TDW 18.5%, YUME 10.2%, ARWR 9.2%, LSCC 8.6%, LOAN 8.5%, CYBR 6%",2016-08-09 19:17:00-04:00,MYGN,negative
878130.0,Myriad Genetics Weak Guidance Drives Shares Down 20%,2016-08-09 16:46:00-04:00,MYGN,negative
878131.0,Myriad Genetics Shares to Resume Trade at 4:35 p.m. EDT,2016-08-09 16:12:00-04:00,MYGN,positive
878132.0,"Myriad Genetics Sees FY17 Adj. EPS $1-$1.10 vs $1.78 Est., Sales $740M-$760M vs $790.6M Est.",2016-08-09 16:12:00-04:00,MYGN,neutral
878133.0,"Myriad Genetics Sees Q1 Adj. EPS $0.25-$0.27 vs $0.43 Est., Sales $168M-$170M vs $192M Est.",2016-08-09 16:11:00-04:00,MYGN,neutral
878134.0,"Myriad Genetics Reports Q4 Adj. EPS $0.36 vs $0.38 Est., Sales $186.5M vs $187.9M Est.",2016-08-09 16:10:00-04:00,MYGN,neutral
878135.0,Myriad Genetics Shares Halted Ahead of Earnings,2016-08-09 16:01:00-04:00,MYGN,positive
878136.0,"Earnings Scheduled For August 9, 2016",2016-08-09 04:04:00-04:00,MYGN,neutral
878137.0,Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health For $225M Upfront And Potential $185M Milestone Payments,2016-08-03 16:05:00-04:00,MYGN,positive
878138.0,Bank of America Downgrades Myriad Genetics to Underperform,2016-07-29 06:40:00-04:00,MYGN,neutral
878139.0,"Myriad Genetics Reports Results from EndoPredict Trial: 'Markedly Outperformed RS (Oncotype DX®) Across the 10-Year Follow-up Period"" in a Large Head-to-Head Breast Cancer Study'",2016-07-11 11:25:00-04:00,MYGN,negative
878140.0,Barclays Explains Its Bullish Call On Myriad Genetics,2016-07-05 10:59:00-04:00,MYGN,neutral
878141.0,Myriad Genetics Reports myChoice HRD Test Successfully Identified Patients Who Met Primary Endpiont in TESARO's Study with Niraparib,2016-06-29 07:16:00-04:00,MYGN,positive
878142.0,Myriad Genetics Subsidiary Crescendo Bioscience Announces New Data On Vectra TO Be Presented In London Today At 11:45am-1:30pm,2016-06-10 07:10:00-04:00,MYGN,neutral
878143.0,Myriad Gets $200 Million More For Share Repurchase Program,2016-06-07 08:42:00-04:00,MYGN,positive
878144.0,Myriad Reports Increase In Buyback Of $200M,2016-06-07 07:06:00-04:00,MYGN,positive
878145.0,Myriad Genetics to Present Three New Hereditary Cancer Studies at the #ASCO16,2016-06-05 08:54:00-04:00,MYGN,negative
878146.0,Myriad Acquires Sividon Diagnostics For E$35M Upfront and E$15M In Additional Performance-Based Milestones,2016-05-31 16:05:00-04:00,MYGN,neutral
878147.0,"UPDATE: Myriad Genetics Says Believes Complaint Lacks Merit, Should Not Be Accepted",2016-05-19 16:58:00-04:00,MYGN,negative
878148.0,"UPDATE: Myriad Genetics Says Has Complied with Requests, Provided Four Patients with Designated Record Set, All Requested Personal Health Info",2016-05-19 16:58:00-04:00,MYGN,neutral
878149.0,Myriad Genetics Issues Statement on HIPAA Complaint from Four Patients,2016-05-19 16:57:00-04:00,MYGN,negative
878150.0,"Top Performing Industries For May 13, 2016",2016-05-13 10:55:00-04:00,MYGN,positive
878151.0,"Worst Performing Industries For May 4, 2016",2016-05-04 11:51:00-04:00,MYGN,negative
878152.0,"Myriad Genetics Reports Q3 Adj. EPS $0.41 vs $0.38 Est., Sales $190.5M vs $184.9M Est.",2016-05-03 16:09:00-04:00,MYGN,neutral
878153.0,Myriad Genetics Sells Off to Low of $36.82 on Vol; Traders Attributing to Short Piece on Street Watchdog,2016-04-25 10:10:00-04:00,MYGN,negative
878154.0,Option Alert: MYGN Jun16 36.0 Puts Sweep: 832 @  ASK  $2.30: 832 traded vs 0 OI:  Earnings 5/3  $36.74 Ref,2016-04-19 09:57:00-04:00,MYGN,positive
878155.0,Myriad Genetics Sells Off to Low of $37.96; Traders Attributing to Negative Leerink Comments,2016-04-19 09:34:00-04:00,MYGN,negative
878156.0,"Downside in Shares of Myriad Genetics Over Last Few Mins May Be Related to Recent Tweet from Probes Reporter '$MYGN  Confirmed, Undisclosed SEC Investigation,' However This Report Was Published Yesterday",2016-03-22 15:20:00-04:00,MYGN,positive
878157.0,Myriad Genetics Downside Intensifies as $37.40 Level Breached; Stock Down ~1.6% to $37.08 for Session,2016-03-22 15:15:00-04:00,MYGN,negative
878158.0,Option Alert: MYGN May16 34.0 Puts Sweep: 2000 @  ASK  $1.25: 2000 traded vs 79 OI:  Earnings 5/3  $37.66 Ref,2016-03-22 14:46:00-04:00,MYGN,positive
878159.0,Myriad Says myRisk Hereditary Cancer Test Identifies 60% More Deleterious Mutations in Patients with Endometrial Cancer,2016-03-18 07:07:00-04:00,MYGN,negative
878160.0,Myriad Genetics Reports Presentation of Second Pivotal Validation Study for myPath Melanoma Test,2016-03-15 07:15:00-04:00,MYGN,neutral
878161.0,Myriad Genetics CEO To Speak Wednesday At 11AM edt On JP Morgan's Life Science & Diagnostics Conf. Call,2016-03-14 10:19:00-04:00,MYGN,positive
878162.0,Myriad Genetics Reports Advancement of Proprietary myVision Variant Classification Tools to Broader Range of Cancer Risk Genes,2016-03-08 07:06:00-05:00,MYGN,negative
878163.0,"Friday's Early Global News: North Korea, Guns And Employment",2016-03-04 12:00:00-05:00,MYGN,neutral
878164.0,Myriad Genetics Announces Expansion of Collaboration with Merck and Tesaro,2016-02-22 07:06:00-05:00,MYGN,neutral
878165.0,"Worst Performing Industries For February 3, 2016",2016-02-03 11:35:00-05:00,MYGN,negative
878166.0,"Myriad Sees Q3 Rev. $183-$185M vs. Est. $190M, EPS $0.37-$0.39 vs. Est. $0.40; FY16 Rev. $750-$770M vs. Est. $759.25M, EPS $1.63-$1.68 vs. Est. $1.64",2016-02-02 16:06:00-05:00,MYGN,neutral
878167.0,"Myriad Genetics Reports Q2 EPS $0.42 vs. Est. $0.41, Rev. $193.3M vs. Est. $189.97M",2016-02-02 16:05:00-05:00,MYGN,neutral
878168.0,"Myriad Genetics, Thermo Fisher Two Top Life Science & Diagnostic Picks At Deutsche Bank",2016-01-07 10:22:00-05:00,MYGN,positive
878169.0,"Avondale Partners Initiates Coverage on Myriad Genetics at Market Outperform, Announces $50.00 PT",2016-01-06 18:07:00-05:00,MYGN,neutral
878170.0,"Deutsche Bank Initiates Coverage on Myriad Genetics at Buy, Calls Co Top Pick",2016-01-06 16:21:00-05:00,MYGN,positive
878171.0,"Genomic Health Upgraded By Canaccord, $44 Per Share Target Predicted",2016-01-06 14:11:00-05:00,MYGN,positive
878172.0,10 Biotechs Short Sellers Are Betting Against,2015-12-29 08:22:00-05:00,MYGN,neutral
878173.0,"Goldman Upgrades Agilent Technologies, FEI Company And Myriad Genetics",2015-12-08 10:19:00-05:00,MYGN,neutral
878174.0,Benzinga's Top Upgrades,2015-12-08 09:01:00-05:00,MYGN,positive
878175.0,"Goldman Sachs Upgrades Myriad Genetics to Neutral, Raises PT to $40.00",2015-12-08 05:36:00-05:00,MYGN,neutral
878176.0,"Myriad Genetics Subsidiary Crescendo Bioscience Says United States Patent and Trademark Office Grants Patent for Vectra DA, Patent Expected To Expire In 2031",2015-12-01 07:08:00-05:00,MYGN,positive
878177.0,Myriad RBM DiscoveryMAP Technology Identifies Novel Biomarkers That May Predict Increased Risk of Cardiovascular Events in Patients With Diabetes,2015-11-16 07:12:00-05:00,MYGN,positive
878178.0,Crescendo Bioscience Vectra DA Data to be Presented at American College of Rheumatology 2015 Annual Meeting,2015-11-07 20:05:00-05:00,MYGN,neutral
878179.0,"Myriad Sees Q2 EPS $0.40-$0.42 vs. Est. $0.35, Rev. $188-$190M vs. Est. $192.57M; FY16 EPS $1.60-$1.65 vs. Est. $1.65, Rev. $750-$770M vs. Est. $758.34M",2015-11-03 16:56:00-05:00,MYGN,neutral
878180.0,"Myriad Genetics Reports Q2 EPS $0.41 Vs Est $0.35, Sales $183.5M vs Est $177.89M",2015-11-03 16:06:00-05:00,MYGN,neutral
878181.0,"Earnings Scheduled For November 3, 2015",2015-11-03 04:20:00-05:00,MYGN,neutral
878182.0,Top 4 NASDAQ Stocks In The Research Services Industry With The Highest EPS,2015-10-19 04:18:00-04:00,MYGN,positive
878183.0,Myriad to Show New Data on Its myRiskHereditary Cancer Test at the CGA-ICC Annual Meeting,2015-10-09 07:05:00-04:00,MYGN,negative
878184.0,US Stock Futures Signal Higher Start On Wall Street,2015-10-07 08:05:00-04:00,MYGN,neutral
878185.0,"Myriad Genetics, Tufts Health Plan Sign 3-Year Contract to Cover Prolaris for Members With Localized Prostate Cancer",2015-10-07 07:07:00-04:00,MYGN,negative
878186.0,Myriad Genetics and Tufts Health Plan Sign Agreement to Cover Prolaris(R) for Members With Localized Prostate Cancer,2015-10-07 07:05:00-04:00,MYGN,negative
878187.0,Myriad Names Jan Schluchter Chief Commercial Officer,2015-10-01 07:05:00-04:00,MYGN,neutral
878188.0,Myriad Genetics Presents New Data on Its Companion Diagnostic and Prostate Cancer Tests at the European Society for Medical Oncology Annual Meeting,2015-09-24 07:05:00-04:00,MYGN,negative
878189.0,Top 4 NASDAQ Stocks In The Research Services Industry With The Highest Revenue,2015-09-17 04:23:00-04:00,MYGN,positive
878190.0,"UBS Maintains Sell on Myriad Genetics, Reserves Caution on Co. Targets, Calls Stock a 'Show-Me' Story",2015-09-15 07:51:00-04:00,MYGN,neutral
878191.0,Myriad Adds to Scientific Evidence for the myPlan(R) Lung Cancer Prognostic Test,2015-09-09 07:07:00-04:00,MYGN,negative
878192.0,"Crescendo Bioscience, Subsidiary Of Myriad Genetics, Names Dr. Elena Hitraya Chief Medical Officer",2015-09-01 07:05:00-04:00,MYGN,neutral
878193.0,Wells Fargo Upgrades Myriad Genetics to Outperform,2015-08-25 07:49:00-04:00,MYGN,positive
878194.0,Myriad Announces Favorable Medicare Final Coverage Decision for the ProlarisR) Test,2015-08-13 07:06:00-04:00,MYGN,positive
878195.0,"Tuesday's After-Hours Movers Led By Fossil, Cree And Myriad",2015-08-11 16:47:00-04:00,MYGN,neutral
878196.0,"Myriad Genetics Reports Q4 Adj. EPS $0.41 vs. Est. $0.42, Rev. $189.9M vs. Est. $187.77M",2015-08-11 16:06:00-04:00,MYGN,neutral
878197.0,"Must Watch Stocks for August 11, 2015",2015-08-11 05:03:00-04:00,MYGN,neutral
878198.0,"Earnings Scheduled For August 11, 2015",2015-08-11 04:03:00-04:00,MYGN,neutral
878199.0,"Fossil Group, Myriad Genetics Among The Earnings Reports To Keep An Eye On Tuesday",2015-08-10 16:27:00-04:00,MYGN,neutral
878200.0,Short-Sellers Betting Against These Biotechs,2015-07-13 16:05:00-04:00,MYGN,neutral
878201.0,11 Stocks With Near-Term Catalysts,2015-07-13 15:32:00-04:00,MYGN,neutral
878202.0,10 Movers To Keep An Eye On This Monday,2015-06-15 08:00:00-04:00,MYGN,neutral
878203.0,Myriad Significantly Improves the myChoice HRD Companion Diagnostic Test,2015-05-29 07:01:00-04:00,MYGN,positive
878204.0,2 Small Cap Pharma Stocks Credit Suisse Loves,2015-05-27 11:10:00-04:00,MYGN,positive
878205.0,Myriad to Present New Clinical Data on Prolaris at AUA 2015 Annual Meeting,2015-05-07 07:07:00-04:00,MYGN,neutral
878206.0,"Myriad Genetics Earlier Said Expecting Q4 Adj. EPS $0.40-$0.42 vs $0.49 Est., Sales $187M-$189M vs $200M Est.; Cuts FY15 EPS Guidance from $1.50-$1.55 to $1.44-$1.46, Sales from $730M-$740M to $720M-$722M vs $734M Est.",2015-05-05 17:17:00-04:00,MYGN,negative
878207.0,"Myriad Genetics Q3 EPS $0.40 vs $0.40 est, Revenue $180M vs $182.4M est",2015-05-05 16:11:00-04:00,MYGN,neutral
878208.0,"Earnings Scheduled For May 5, 2015",2015-05-05 04:27:00-04:00,MYGN,neutral
878209.0,11 Buyout Targets Credit Suisse Is Watching,2015-04-29 13:53:00-04:00,MYGN,positive
878210.0,Top 4 Stocks In The Research Services Industry With The Highest Revenue,2015-04-02 05:45:00-04:00,MYGN,positive
878211.0,Myriad's Downside Case Might Not Matter,2015-04-01 15:25:00-04:00,MYGN,negative
878212.0,"Myriad, AstraZeneca Expand Research Collaboration on Lynparza",2015-04-01 07:09:00-04:00,MYGN,positive
878213.0,"Goldman Sachs Cuts Myriad Genetics To Sell, Ups Alere",2015-03-26 15:33:00-04:00,MYGN,negative
878214.0,"Goldman Sachs Downgrades Myriad Genetics to Sell, Lowers PT to $25.00",2015-03-26 04:49:00-04:00,MYGN,negative
878215.0,US Stock Futures Signal Higher Start On Wall Street,2015-03-20 07:39:00-04:00,MYGN,neutral
878216.0,Myriad Announces Prolaris Test Biopsy Results from EMPATHY-P Study at European Association of Urology Annual Meeting,2015-03-20 04:40:00-04:00,MYGN,neutral
878217.0,"Myriad, BioMarin Expand Collaboration to Evaluate myChoice HRD as a Companion Diagnostic for Talazoparib",2015-03-17 07:06:00-04:00,MYGN,positive
878218.0,UBS Initiates Coverage on Myriad Genetics at Sell,2015-03-10 07:14:00-04:00,MYGN,neutral
878219.0,Myriad Publishes myPath Melanoma Pivotal Validation Study in Journal of Cutaneous Pathology,2015-03-04 07:09:00-05:00,MYGN,neutral
878220.0,Heavy News Day For Several Biotech Stocks,2015-02-25 15:34:00-05:00,MYGN,neutral
878221.0,Myriad Approves $200M Buyback Program,2015-02-24 16:08:00-05:00,MYGN,positive
878222.0,Top 5 Biotech Stocks That The Smart Money Doesn't Like,2015-02-17 12:17:00-05:00,MYGN,positive
878223.0,"Quest Diagnostics, Myriad Genetics Dismiss BRCA Gene Patent Litigation",2015-02-09 08:47:00-05:00,MYGN,negative
878224.0,"JMP Securities Upgrades Myriad Genetics, Says 'Revised Guidance Lowers The Bar'",2015-02-04 12:03:00-05:00,MYGN,positive
878225.0,Morning Market Losers,2015-02-04 09:54:00-05:00,MYGN,negative
878226.0,"Wednesday Morning Movers: Gilead Sciences, Myriad Genetics Tumble Following Earnings",2015-02-04 09:39:00-05:00,MYGN,neutral
878227.0,Benzinga's Top Upgrades,2015-02-04 08:40:00-05:00,MYGN,positive
878228.0,Benzinga's Top #PreMarket Losers,2015-02-04 08:16:00-05:00,MYGN,negative
878229.0,JMP Securities Upgrades Myriad Genetics To Outperform,2015-02-04 07:43:00-05:00,MYGN,positive
878230.0,"JMP Securities Upgrades Myriad Genetics to Market Outperform, Announces $50.00 PT",2015-02-04 05:53:00-05:00,MYGN,positive
878231.0,"Mizuho Securities Downgrades Myriad Genetics to Neutral, Lowers PT to $32.00",2015-02-04 04:38:00-05:00,MYGN,positive
878232.0,"Credit Suisse Downgrades Myriad Genetics to Underperform, Lowers PT to $30.00",2015-02-04 03:59:00-05:00,MYGN,positive
878233.0,"Tuesday's After-Hours Movers: Gilead, Wynn Resorts And Chipotle Fall Following Earnings",2015-02-03 17:53:00-05:00,MYGN,neutral
878234.0,Myriad Genetics Resumes Trading Down Over 19%,2015-02-03 16:42:00-05:00,MYGN,neutral
878235.0,"Myriad Announces Retirement of Peter Meldrum President, CEO",2015-02-03 16:28:00-05:00,MYGN,neutral
878236.0,PREVIEW: Myriad Genetics to Resume Trading at 4:40 PM ET,2015-02-03 16:15:00-05:00,MYGN,neutral
878237.0,"Myriad Genetics  Reports Q2 APS $0.32 Vs Est $0.35, Sales $184.4M Vs Est $183.41M",2015-02-03 16:06:00-05:00,MYGN,neutral
878238.0,Myriad Genetics Shares Halted News Pending,2015-02-03 16:01:00-05:00,MYGN,positive
878239.0,"Earnings Scheduled For February 3, 2015",2015-02-03 04:59:00-05:00,MYGN,neutral
878240.0,"Myriad, Pathway Genomics Settle BRCA Patent Infringement Case",2015-01-23 15:41:00-05:00,MYGN,negative
878241.0,Big Short Interest On These 5 Biotech Stocks,2015-01-12 15:36:00-05:00,MYGN,positive
878242.0,Myriad Obtains CE Mark for Tumor BRACAnalysis CDx; Launches Test in Europe as Companion Diagnostic for PARP Inhibitors,2015-01-08 04:58:00-05:00,MYGN,negative
878243.0,"Barclays Initiates Coverage On Life Science Tools & Diagnostics, Names Thermo Fisher As 'Top Pick'",2015-01-07 16:41:00-05:00,MYGN,positive
878244.0,Myriad Receives FDA Approval of BRACAnalysis CDx,2014-12-19 12:11:00-05:00,MYGN,positive
878245.0,"Shares of Myriad Genetics Fall ~2.5% Following Chatter of Lost Appeals Court Bid, Now Down ~1.6% for Session",2014-12-17 10:21:00-05:00,MYGN,neutral
878246.0,"Myriad Has Lost Appeals Court Bid to Block Breast Cancer Tests, Patents Found Invalid",2014-12-17 10:19:00-05:00,MYGN,negative
878247.0,Hearing Myriad Genetics Lost CAFC Hearing,2014-12-17 10:13:00-05:00,MYGN,negative
878248.0,A Closer Look At 5 Heavily Shorted Stocks,2014-12-12 11:02:00-05:00,MYGN,neutral
878249.0,Study Shows Prolaris Could Save Healthcare System $6B Over 10 Yrs.,2014-12-02 07:03:00-05:00,MYGN,positive
878250.0,TESARO and Myriad Genetics Form Collaboration Utilizing Myraid's myChoice HRD Companion Diagnostic,2014-11-20 07:47:00-05:00,MYGN,neutral
878251.0,Myriad Genetics' Crescendo Bioscience Offers New Clinical Data on Vectra(R) DA at ACR,2014-11-19 07:07:00-05:00,MYGN,neutral
878252.0,Crescendo Bioscience Highlights New Clinical Data on Vectra DA at ACR,2014-11-19 07:06:00-05:00,MYGN,neutral
878253.0,"Top Performing Industries For November 12, 2014",2014-11-12 10:59:00-05:00,MYGN,positive
878254.0,UPDATE: Morgan Stanley Initiates Coverage On Myriad Genetics As Survey Points To Greater Share Loss,2014-11-10 09:15:00-05:00,MYGN,positive
878255.0,Benzinga's Top Initiations,2014-11-10 09:04:00-05:00,MYGN,positive
878256.0,Morgan Stanley Initiates Myriad Genetics With Underperform,2014-11-10 08:47:00-05:00,MYGN,neutral
878257.0,Crescendo Bioscience To Feature New Data On Vectra DA At 2014 ACR Meeting,2014-11-10 07:43:00-05:00,MYGN,neutral
878258.0,"Morgan Stanley Initiates Coverage on Myriad Genetics, Inc. at Underperform, Announces $25.00 PT",2014-11-10 04:19:00-05:00,MYGN,neutral
878259.0,"Myriad Genetics, Inc. Sees Q2 EPS $0.33-0.36; Sees Sales $180.0M-185.0M",2014-11-04 16:34:00-05:00,MYGN,neutral
878260.0,"Myriad Genetics, Inc. Sees FY2015 EPS $1.90-2.00; Sees Sales $800.0M-820.0M",2014-11-04 16:34:00-05:00,MYGN,neutral
878261.0,"Myriad Genetics, Inc. Reports Q1 EPS of $0.25 vs $0.32 Est; Revenue of $168.80M vs $174.99M Est",2014-11-04 16:22:00-05:00,MYGN,neutral
878262.0,"Earnings Scheduled For November 4, 2014",2014-11-04 05:31:00-05:00,MYGN,neutral
878263.0,Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) ,2014-11-03 07:10:00-05:00,MYGN,positive
878264.0,Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe ,2014-10-24 09:00:00-04:00,MYGN,negative
878265.0,TGIF As Markets Rally; S&P 500 Posts Longest Weekly Loss Streak Since 2011,2014-10-17 16:43:00-04:00,MYGN,positive
878266.0,Morning Market Losers ,2014-10-17 10:03:00-04:00,MYGN,negative
878267.0,Shares of Myriad Genetics to Resume Trade at 7:35 a.m. EDT,2014-10-17 07:31:00-04:00,MYGN,positive
878268.0,"Myriad Reports Received Draft Medicare Coverage for Polaris(R); Reports Prelim. Q1 Adj. EPS $0.25 vs $0.41 Est., Sales $168M vs $183.5M Est., Reaffirms FY15 Outlook",2014-10-17 07:06:00-04:00,MYGN,neutral
878269.0,Myriad Genetics Shares Halted News Pending,2014-10-17 07:00:00-04:00,MYGN,positive
878270.0,Capital World Investors Reports 10.5% Passive Stake In Myriad Genetics as of September 30,2014-10-09 14:55:00-04:00,MYGN,positive
878271.0,Myriad Appoints R. Bryan Riggsbee As CFO,2014-10-08 16:07:00-04:00,MYGN,neutral
878272.0,Myriad Reports Tumor Bracanalysis CDX Has Identified 44% More Candidates for PARP Therapy,2014-09-29 07:40:00-04:00,MYGN,negative
878273.0,Myriad Genetics Shares Spike to High,2014-09-22 10:13:00-04:00,MYGN,positive
878274.0,Myriad myPath Melanoma Test Reduced Indeterminate Cases By 76% And Changed Treatment In 35 % Of Cases,2014-09-09 07:08:00-04:00,MYGN,neutral
878275.0,Myriad Publishes myRisk Hereditary Cancer Study In Cancer,2014-09-03 16:06:00-04:00,MYGN,negative
878276.0,"Other Highlights from Tiger Global 13F: New Stake in Netflix, Liquidated Stake in Gap, Raised Stake in Charter, Lowered Stakes in Priceline, Myriad Genetics",2014-08-14 14:30:00-04:00,MYGN,negative
878277.0,FuelCell Upgrade; Amazon Announces New Product,2014-08-13 15:28:00-04:00,MYGN,positive
878278.0,SeaWorld Drops On Downbeat Results; Canadian Solar Shares Surge,2014-08-13 12:49:00-04:00,MYGN,positive
878279.0,Markets Rise; Macy's Lowers Comparable Sales Outlook,2014-08-13 10:59:00-04:00,MYGN,negative
878280.0,Morning Market Losers ,2014-08-13 09:51:00-04:00,MYGN,negative
878281.0,"Myriad Genetics, Inc. Sees FY2015 EPS $1.90-2.00 Which May Not Compare $2.39 Est; Sees Sales $800.0M-820.0M Which May Not Compare $776.60M Est",2014-08-12 16:06:00-04:00,MYGN,neutral
878282.0,"Myriad Genetics, Inc. Reports Q4 EPS of $0.48 vs $0.46 Est; Revenue of $188.80M vs $187.68M Est",2014-08-12 16:05:00-04:00,MYGN,neutral
878283.0,"Earnings Scheduled For August 12, 2014",2014-08-12 05:16:00-04:00,MYGN,neutral
878284.0,Top 4 Stocks In The Research Services Industry With The Highest Profit Margin,2014-08-01 05:16:00-04:00,MYGN,positive
878285.0,Top 4 NASDAQ Stocks In The Research Services Industry With The Highest EPS,2014-07-18 04:36:00-04:00,MYGN,positive
878286.0,Myriad Genetics Shares Spike to High,2014-06-27 15:52:00-04:00,MYGN,positive
878287.0,Form 8-K from Myriad Genetics Shows CFO James Evans Will Retire,2014-06-09 17:13:00-04:00,MYGN,neutral
878288.0,Mriad Announces James Evans CFO,2014-06-09 16:05:00-04:00,MYGN,neutral
878289.0,Myriad Genetics Announces Partnership Aimed at Accelerating Hereditary Cancer Research,2014-06-02 10:46:00-04:00,MYGN,negative
878290.0,Myriad Presents Clinical Data on Myriad myRisk Hereditary Cancer Test at ASCO 2014,2014-06-02 07:17:00-04:00,MYGN,negative
878291.0,US Stock Futures Edge Lower Ahead Of Consumer Spending Report,2014-05-30 07:21:00-04:00,MYGN,negative
878292.0,"Myriad Genetics Says Will Present Data on BRACAnalysis CDx(TM), HRD(TM) at 2014 ASCO Meeting",2014-05-30 07:11:00-04:00,MYGN,neutral
878293.0,Myriad Says  Test Predicts Mortality Risk For Prostate Cancer,2014-05-20 07:06:00-04:00,MYGN,negative
878294.0,"13F from Tiger Global Shows Raised Stakes in Charter, Myriad Genetics, Vipshops, Reduced Stakes in Mastercard, Motorola, New Stakes in Zillow, Trulia, Avis, Liquidated Stakes in Amazon, Netflix, Yahoo!, Groupon, TripAdvisor",2014-05-15 14:10:00-04:00,MYGN,positive
878295.0,Myriad Subsidiary Crescendo Bioscience's Vectra DA Predicts Radiographic Progression in Patients With Early RA,2014-05-14 07:08:00-04:00,MYGN,neutral
878296.0,"Myriad Genetics, Inc. Reports Q3 EPS of $0.48 vs $0.45 Est; Revenue of $182.90M vs $175.23M Est",2014-05-06 16:07:00-04:00,MYGN,neutral
878297.0,Myriad Genetics and UnitedHealthcare Sign 3 Yr Deal To Make Cancer Tests Available To United Members,2014-05-06 07:16:00-04:00,MYGN,negative
878298.0,"Earnings Scheduled For May 6, 2014",2014-05-06 05:33:00-04:00,MYGN,neutral
878299.0,Myriad to Launch EndoPredict In Canada,2014-05-01 07:34:00-04:00,MYGN,neutral
878300.0,Top 4 NASDAQ Stocks In The Research Services Industry With The Highest Revenue,2014-04-23 04:31:00-04:00,MYGN,positive
878301.0,Daniel B. Ravicher Tweet:  'Fed Cir Court of Appeals denies Myriad Genetics' $MYGN motion to expedite appeal of denial of preliminary injunction against Ambry',2014-04-14 10:27:00-04:00,MYGN,negative
878302.0,"Bank of America Maintains Neutral on Myriad Genetics, Inc., Raises PO to $42.00",2014-04-14 07:05:00-04:00,MYGN,negative
878303.0,UPDATE: Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R),2014-04-07 16:31:00-04:00,MYGN,positive
878304.0,Myriad Genetics Submits Premarket Approval to FDA for Bracanalysis,2014-04-07 16:30:00-04:00,MYGN,positive
878305.0,"Mizuho Securities Upgrades Myriad Genetics, Inc. to Buy",2014-04-04 07:48:00-04:00,MYGN,positive
878306.0,Mid-Afternoon Market Update: MannKind Hangs Onto its Gains as Yelp Shares Drop,2014-04-02 15:33:00-04:00,MYGN,positive
878307.0,Mid-Day Market Update: Apollo Drops After Q2 Results; MannKind Shares Spike Higher,2014-04-02 12:31:00-04:00,MYGN,positive
878308.0,Mid-Morning Market Update: Markets Flat; Monsanto Earnings Beat Street View,2014-04-02 10:38:00-04:00,MYGN,neutral
878309.0,Benzinga's Volume Movers,2014-04-02 10:35:00-04:00,MYGN,neutral
878310.0,Morning Market Movers,2014-04-02 09:40:00-04:00,MYGN,neutral
878311.0,J.P. Morgan Reinstates Underweight Rating on Myriad Over LT Outlook Concerns,2014-03-31 10:41:00-04:00,MYGN,neutral
878312.0,"JP Morgan Reinstates Underweight on Myriad Genetics, Inc., Announces $25.00 PT",2014-03-31 07:53:00-04:00,MYGN,positive
878313.0,Top 4 Stocks In The Research Services Industry With The Lowest PEG Ratio,2014-03-27 04:30:00-04:00,MYGN,negative
878314.0,Myriad Announces HRD Companion Diagnostic Collaboration With Tesaro ,2014-03-24 07:09:00-04:00,MYGN,neutral
878315.0,Myriad Genetics Reports SGO Issued New Clinical Practice Statements Regarding Hereditary Cancer Testing ,2014-03-20 07:08:00-04:00,MYGN,negative
878316.0,Market Wrap For March 11: Markets End Slightly In The Red As Ukraine Worries Persist And Continued Chinese Conerns,2014-03-11 16:42:00-04:00,MYGN,negative
878317.0,Mid-Afternoon Market Update: Fuel Cell Companies Reverse Sharply on Citron Research Report,2014-03-11 16:05:00-04:00,MYGN,neutral
878318.0,Mid-Day Market Update: Men's Wearhouse To Acquire Jos. A. Bank For $65/Share; Myriad Shares Slip,2014-03-11 12:42:00-04:00,MYGN,positive
878319.0,"Mid Morning Losers for March 11th, 2014",2014-03-11 11:20:00-04:00,MYGN,negative
878320.0,Mid-Morning Market Update: Markets Edge Lower; American Eagle Issues Weak Profit Forecast,2014-03-11 10:23:00-04:00,MYGN,negative
878321.0,Morning Market Losers ,2014-03-11 09:42:00-04:00,MYGN,negative
878322.0,Myriad Genetics Shares Fall 8% Premarket as Company Fails to Block Competitor Ambry Genetics,2014-03-11 08:34:00-04:00,MYGN,negative
878323.0,Benzinga's Top #PreMarket Losers,2014-03-11 08:18:00-04:00,MYGN,negative
878324.0,Myriad Genetics' Motion to Block Rival Denied by US Court,2014-03-11 07:48:00-04:00,MYGN,negative
878325.0,"Myriad Genetics Issues Clinical Utility Study for Prolaris, Says Submitted Procede 500 Data to CMS for Medicare, Expecting Coverage by the End of June",2014-03-03 07:20:00-05:00,MYGN,neutral
878326.0,10 Healthcare Stocks With Strong Growth For 2014: Investment Idea Of The Day,2014-02-26 12:54:00-05:00,MYGN,positive
878327.0,Investing Like Martin Zweig: Growth With A Conservative Streak,2014-02-19 15:28:00-05:00,MYGN,positive
878328.0,New Stocks Make Most Attractive/Dangerous Lists For February,2014-02-18 15:10:00-05:00,MYGN,neutral
878329.0,Myriad Genetics Publishes Positive Prolaris Data in the Journal of Urology ,2014-02-18 07:10:00-05:00,MYGN,positive
878330.0,"Market Wrap For February 7: Jobs Report Not Great, But Not Too Bad",2014-02-07 16:36:00-05:00,MYGN,positive
878331.0,US Stock Futures Up; All Eyes On Jobs Report,2014-02-07 07:14:00-05:00,MYGN,neutral
878332.0,"Credit Suisse Upgrades Myriad Genetics, Inc. to Neutral",2014-02-07 06:59:00-05:00,MYGN,positive
878333.0,Mid-Afternoon Market Update: Sprint Rises on News it Has the Financing to Acquire T-Mobile,2014-02-05 15:29:00-05:00,MYGN,neutral
878334.0,Mid-Day Market Update: CH Robinson Shares Drop On Downbeat Results; Tableau Spikes Higher,2014-02-05 13:02:00-05:00,MYGN,neutral
878335.0,Mid-Morning Market Update: Markets Open Lower; Time Warner Earnings Beat Street View,2014-02-05 10:28:00-05:00,MYGN,negative
878336.0,Benzinga's Top #PreMarket Gainers,2014-02-05 08:06:00-05:00,MYGN,positive
878337.0,Safeguard Scientifics Expects to Realize Approximately $40M In Aggregate Cash Proceeds from Acquisition of Partner Crescendo Bioscience by Myriad Genetics,2014-02-05 06:14:00-05:00,MYGN,positive
878338.0,"Stocks To Watch For February 5, 2014",2014-02-05 04:09:00-05:00,MYGN,neutral
878339.0,"Benzinga's  M&A Chatter for Tuesday February 4, 2014",2014-02-04 17:30:00-05:00,MYGN,neutral
878340.0,Myriad Genetics Shares Resume Trade Up 14%,2014-02-04 16:35:00-05:00,MYGN,positive
878341.0,Myriad Genetics Shares to Resume Trade at 4:35PM EST,2014-02-04 16:12:00-05:00,MYGN,positive
878342.0,"Myriad Genetics, Inc. Sees FY2014 Sales $740.0M-750.0M vs $705.60M Est",2014-02-04 16:10:00-05:00,MYGN,neutral
878343.0,Myriad Genetics Raises FY 2014 Guidance ,2014-02-04 16:09:00-05:00,MYGN,neutral
878344.0,"Myriad Genetics, Inc. Reports Q2 EPS of $0.66 vs $0.46 Est; Revenue of $204.10M vs $176.02M Est",2014-02-04 16:08:00-05:00,MYGN,neutral
878345.0,Myriad Genetics to Buy Crescendo Bioscience for $270M in Cash,2014-02-04 16:03:00-05:00,MYGN,neutral
878346.0,Myriad Genetics Halted News PEnding,2014-02-04 16:01:00-05:00,MYGN,neutral
878347.0,"Earnings Scheduled For February 4, 2014",2014-02-04 04:14:00-05:00,MYGN,neutral
878348.0,Market Wrap For December 31: Markets End The Year On A Positive Note,2013-12-31 16:29:00-05:00,MYGN,positive
878349.0,Bank of America Lowers PO on Myriad Genetics Following BRACA Pricing Cut,2013-12-31 13:16:00-05:00,MYGN,negative
878350.0,"Bank of America Maintains Neutral on Myriad Genetics, Inc., Lowers PO to $25.00",2013-12-31 06:53:00-05:00,MYGN,negative
878351.0,Market Wrap For December 30: Markets Quiet Ahead of New Year's Eve,2013-12-30 16:41:00-05:00,MYGN,neutral
878352.0,Mid-Afternoon Market Update: Markets Roughly Flat as Social Media Names Slowly Recover Morning Losses,2013-12-30 15:27:00-05:00,MYGN,negative
878353.0,Mid-Day Market Update: Crocs Surges After Blackstone Investment Announcement; Twitter Shares Slip,2013-12-30 13:04:00-05:00,MYGN,positive
878354.0,Stocks Hitting 52-Week Lows,2013-12-30 10:37:00-05:00,MYGN,negative
878355.0,Morning Market Losers ,2013-12-30 10:24:00-05:00,MYGN,negative
878356.0,Benzinga's Top Downgrades,2013-12-30 09:38:00-05:00,MYGN,positive
878357.0,"Mizuho Securities Downgrades Myriad Genetics, Inc. to Neutral, Maintains $24.00 PT",2013-12-30 09:24:00-05:00,MYGN,positive
878358.0,Benzinga's Top #PreMarket Losers,2013-12-30 08:23:00-05:00,MYGN,negative
878359.0,"Myriad Genetics Expresses Concerns over CMS Not Valuing  BRCA 2 Gene in 81211 Code, CMS 81211 Payment Rate  -8K",2013-12-30 08:07:00-05:00,MYGN,negative
878360.0,"Stocks To Watch For December 16, 2013",2013-12-16 04:22:00-05:00,MYGN,neutral
878361.0,Myriad's Presents Positive Clinical Data on HRD Test at SABCS 2013,2013-12-14 08:33:00-05:00,MYGN,positive
878362.0,Myriad Genetics Announces Collaboration With Janssen ,2013-12-09 07:01:00-05:00,MYGN,neutral
878363.0,Myriad Genetics to Present Prolaris Data ,2013-12-04 07:05:00-05:00,MYGN,neutral
878364.0,Mid-Day Market Update: Dow Down Over 100 Points; Apple Shares Gain,2013-12-03 12:23:00-05:00,MYGN,positive
878365.0,UPDATE: JMP Securities Downgrades Myriad Genetics as Survey Hints at More Rapid Share Losses Than Anticipated,2013-12-03 10:51:00-05:00,MYGN,positive
878366.0,"JMP Securities Downgrades Myriad Genetics, Inc. to Market Perform, Removes $36.00 PT",2013-12-03 07:50:00-05:00,MYGN,positive
878367.0,Hearing Positive Cowen Comments on Myriad Genetics,2013-12-02 10:41:00-05:00,MYGN,positive
878368.0,Invitae Files Patent Infringement Suit Against Myriad Genetics ,2013-12-02 08:05:00-05:00,MYGN,negative
878369.0,Invitae Responds Being Names as Defendant in Myriad Genetics Lawsuit ,2013-11-26 17:07:00-05:00,MYGN,negative
878370.0,Myriad Genetics Says Received Second HRD Pact with BioMarin,2013-11-20 07:05:00-05:00,MYGN,neutral
878371.0,Myriad Genetics Will Buyback Up to $300M,2013-11-05 16:43:00-05:00,MYGN,neutral
878372.0,"Myriad Genetics, Inc. Reports Q1 EPS of $0.68 vs $0.46 Est; Revenue of $202.50M vs $167.64M Est",2013-11-05 16:06:00-05:00,MYGN,neutral
878373.0,US Stock Futures Up; Apple Earnings In Focus,2013-10-28 07:20:00-04:00,MYGN,neutral
878374.0,Myriad myPlan Lung Cancer Test Met Primary Endpoint in Validation Study ,2013-10-28 07:07:00-04:00,MYGN,negative
878375.0,Myriad Genetics Says myRisk Cancer Test Highly Accurate in Key Validation Study,2013-10-24 07:17:00-04:00,MYGN,negative
878376.0,"Option Alert: Myriad Genetics November 27 Call; 2,250 Contracts Traded @$1.05; Currently $25.16",2013-10-23 13:57:00-04:00,MYGN,positive
878377.0,"Jefferies Maintains Hold on Myriad Genetics, Inc., Lowers PT to $24.00",2013-10-22 07:30:00-04:00,MYGN,negative
878378.0,"Option Alert: Myriad Genetics November 30 Call; 2,000 Contracts Traded @$0.45; Currently $24.02",2013-10-21 10:31:00-04:00,MYGN,positive
878379.0,UPDATE: Credit Suisse Downgrades Myriad Genetics on Unclear Growth Potential,2013-10-21 09:33:00-04:00,MYGN,positive
878380.0,"Credit Suisse Downgrades Myriad Genetics, Inc. to Underperform, Lowers PT to $20.00",2013-10-21 08:22:00-04:00,MYGN,positive
878381.0,"Option Alert: Myriad Genetics November 27 Call; 2,019 Contracts Traded @$1.15; Currently $24.77",2013-10-18 11:10:00-04:00,MYGN,positive
878382.0,"Option Alert: Myriad Genetics November 26 Call, 1,850 Contracts Traded @$1.05; Currently $24.75",2013-10-17 11:40:00-04:00,MYGN,positive
878383.0,Myriad Says myPath Melanoma Test Highly Effective in Verification Study,2013-10-14 07:07:00-04:00,MYGN,positive
878384.0,UPDATE: SunTrust Initiates Coverage on Myriad Genetics on Pricing Risk,2013-10-11 10:25:00-04:00,MYGN,negative
878385.0,"SunTrust Robinson Humphrey Initiates Coverage on Myriad Genetics, Inc. at Reduce, Announces $17.00 PT",2013-10-10 17:04:00-04:00,MYGN,neutral
878386.0,Myriad Genetics Reports myRisk Cancer Test Improves Colon Cancer Testing by 60%,2013-10-07 07:09:00-04:00,MYGN,negative
878387.0,"Market Wrap For Tuesday, October 1: Government Down, Markets Up",2013-10-01 16:36:00-04:00,MYGN,neutral
878388.0,Mid-Afternoon Market Update: Markets Remain Up As Government Shutdown Continues,2013-10-01 15:17:00-04:00,MYGN,neutral
878389.0,Mid-Day Market Update: US Stocks Extend Gains; Lexicon Shares Surge,2013-10-01 13:24:00-04:00,MYGN,positive
878390.0,Mid-Morning Market Update: Markets Rise; Walgreen Earnings Surge 86%,2013-10-01 10:48:00-04:00,MYGN,neutral
878391.0,Morning Market Movers ,2013-10-01 09:47:00-04:00,MYGN,neutral
878392.0,Benzinga's Top Pre-Market Gainers,2013-10-01 08:39:00-04:00,MYGN,positive
878393.0,"Ladenburg Thalmann Upgrades Myriad Genetics, Inc. to Buy",2013-10-01 08:09:00-04:00,MYGN,neutral
878394.0,Myriad Gentics Reports in 8-K Filing that CPT Code Pricing Error Should Take a 'Week or Two' to Correct,2013-10-01 06:33:00-04:00,MYGN,negative
878395.0,Selloff in Myriad Genetics May be attributed to 2013 Gapfill Payment Amounts - Clinical Laboratory Fee Schedule (CLFS) Posted on CMS.gov,2013-09-30 15:54:00-04:00,MYGN,neutral
878396.0,Myriad Genetics Spikes Lower,2013-09-30 15:49:00-04:00,MYGN,negative
878397.0,"US Stock Futures Drop Ahead Of New Home Sales, Durable Goods Data",2013-09-25 07:18:00-04:00,MYGN,negative
878398.0,UPDATE: Myriad's myPlan Lung Cancer Test Meets Primary Endpoint in Trial,2013-09-25 07:02:00-04:00,MYGN,negative
878399.0,Myriad's myPlan Lung Cancer Test Meets Primary Endpoint in Trial,2013-09-25 07:01:00-04:00,MYGN,negative
878400.0,Shares of Myriad Genetics Move Lower as Co. Reports Launch of myRisk Hereditary Cancer Panel,2013-09-05 08:59:00-04:00,MYGN,negative
878401.0,"Myriad Genetics, AstraZeneca Expand Collaboration on Olaparib Phase 3 Clinical Trials ",2013-09-04 06:05:00-04:00,MYGN,positive
878402.0,"The Top 10 Financial Tweets For Thursday, August 29",2013-08-29 12:45:00-04:00,MYGN,positive
878403.0,"Myriad Genetics, Inc. Sees FY2014 EPS $1.87-1.94 vs $1.85 Est; Sees Sales $690.0M-710.0M vs $663.30M Est",2013-08-13 16:16:00-04:00,MYGN,neutral
878404.0,"Myriad Genetics, Inc. Reports Q4 EPS of $0.53 vs $0.44 Est; Revenue of $174.10M vs $159.87M Est",2013-08-13 16:06:00-04:00,MYGN,neutral
878405.0,"Earnings Scheduled For August 13, 2013",2013-08-13 05:58:00-04:00,MYGN,neutral
878406.0,Myriad and TESARO Enter Into Companion Diagnostic Agreement,2013-06-24 16:06:00-04:00,MYGN,positive
878407.0,"DaVita, Myriad RBM Announce Biomarker Research Collaboration ",2013-06-17 07:07:00-04:00,MYGN,neutral
878408.0,Mid-Afternoon Market Update: Walter Energy Plummets as Oil Posts a Strong Rally,2013-06-14 15:42:00-04:00,MYGN,positive
878409.0,Afternoon Market Losers,2013-06-14 14:01:00-04:00,MYGN,negative
878410.0,"Mid-Day Market Update: Stocks Move Lower, Groupon Rises on Analyst Upgrade",2013-06-14 12:54:00-04:00,MYGN,negative
878411.0,'Happy Birthday' the Subject of Newest Copyright Litigation,2013-06-14 11:37:00-04:00,MYGN,positive
878412.0,Hearing Piper Defending Myriad Genetics,2013-06-14 11:13:00-04:00,MYGN,neutral
878413.0,"Mid-Morning Market Update: Markets Slightly Higher, Smithfield Posts Lower Profit",2013-06-14 10:21:00-04:00,MYGN,positive
878414.0,UPDATE: Bank of America Downgrades Myriad Genetics as Competitive Concerns Emerge ,2013-06-14 08:36:00-04:00,MYGN,positive
878415.0,Benzinga's Top Pre-Market Losers,2013-06-14 08:23:00-04:00,MYGN,negative
878416.0,Myriad Ruling Causes 15 Percent Swing Thursday – Here's Why,2013-06-14 08:03:00-04:00,MYGN,neutral
878417.0,Benzinga's Top Downgrades,2013-06-14 07:32:00-04:00,MYGN,positive
878418.0,"JMP Securities Upgrades Myriad Genetics, Inc. to Market Outperform, Announces $48.00 PT",2013-06-14 07:27:00-04:00,MYGN,positive
878419.0,"RBC Capital Downgrades Myriad Genetics, Inc. to Sector Perform, Maintains $32.00 PT",2013-06-14 07:27:00-04:00,MYGN,neutral
878420.0,"Bank of America Downgrades Myriad Genetics, Inc. to Neutral, Lowers PO to $35.00",2013-06-14 06:52:00-04:00,MYGN,negative
878421.0,"Market Wrap for Thursday, June 13: Strong Economic Reports Trigger Stock Rally ",2013-06-13 16:24:00-04:00,MYGN,positive
878422.0,"DJ Reporting Quest Diagnostics to Offer BRCA1, BRCA2 Test Later This Year",2013-06-13 15:35:00-04:00,MYGN,neutral
878423.0,UPDATE: Myriad Shares Have Swung from Up Nearly 8% to Down 4% Over Last Hour,2013-06-13 15:24:00-04:00,MYGN,positive
878424.0,Myriad Genetics Shares Selling Off ,2013-06-13 15:22:00-04:00,MYGN,positive
878425.0,"Leerink Swann Downgrades Myriad Genetics, Inc. to Market Perform",2013-06-13 14:32:00-04:00,MYGN,neutral
878426.0,Hearing CFRA Negative on Myriad Supreme Court Decision,2013-06-13 13:57:00-04:00,MYGN,neutral
878427.0,"Mizuho's Lawson Boosts Target on Myriad Genetics Shares from $38 to $43, Maintains Buy",2013-06-13 13:50:00-04:00,MYGN,positive
878428.0,Afternoon Market Gainers ,2013-06-13 13:06:00-04:00,MYGN,neutral
878429.0,Supreme Court Upholds Myriad's cDNA Patent Claims,2013-06-13 12:27:00-04:00,MYGN,positive
878430.0,"UPDATE: Myriad Shares Pulling Back Very Slightly, Now Up 5-7%",2013-06-13 10:32:00-04:00,MYGN,positive
878431.0,Myriad Shares Resume Now Up 8%,2013-06-13 10:31:00-04:00,MYGN,positive
878432.0,UPDATE: Myriad Genetics Shares Halted Up 4.4%,2013-06-13 10:26:00-04:00,MYGN,positive
878433.0,"Myriad Genetics Shares Halted on Limit-Up, Limit-Down",2013-06-13 10:26:00-04:00,MYGN,positive
878434.0,"Myriad Genetics Shares Now Spike Higher, Now Up 4+%",2013-06-13 10:25:00-04:00,MYGN,positive
878435.0,Supreme Court Ruling Said to be Partial Victory for Myriad,2013-06-13 10:25:00-04:00,MYGN,positive
878436.0,Mondaq Reporting Gene Patents Limited by High Court in Mixed Ruling for Myriad,2013-06-13 10:23:00-04:00,MYGN,negative
878437.0,Myriad Genetics Spikes Lower,2013-06-13 10:22:00-04:00,MYGN,negative
878438.0,UPDATE: Cantor Fitzgerald Initiates Coverage on Myriad Genetics on Position in Molecular Diagnostic Franchises,2013-06-07 09:43:00-04:00,MYGN,neutral
878439.0,"Cantor Fitzgerald Initiates Coverage on Myriad Genetics, Inc. at Buy, Announces $40.00 PT",2013-06-06 16:18:00-04:00,MYGN,neutral
878440.0,"UPDATE: Jefferies Assumes Coverage on Myriad Genetics, Downgrades to Hold Ahead of SCOTUS Decision",2013-05-31 10:58:00-04:00,MYGN,neutral
878441.0,"Jefferies Initiates Coverage on Myriad Genetics, Inc. at Hold, Announces $31.00 PT",2013-05-31 08:38:00-04:00,MYGN,neutral
878442.0,US Stock Futures Down Ahead Profit Taking,2013-05-15 06:03:00-04:00,MYGN,positive
878443.0,"Stocks To Watch For May 15, 2013",2013-05-15 04:31:00-04:00,MYGN,neutral
878444.0,"Myriad Genetics Targeting Five-Year Low-Mid Double-Digit Sales Growth, Mid Double-Digit EPS Growth, Oper. Margins Mid-to-High 30%'s",2013-05-09 09:11:00-04:00,MYGN,positive
878445.0,"Mizuho Securities Upgrades Myriad Genetics, Inc. to Buy, Raises PT to $34.00",2013-05-08 08:20:00-04:00,MYGN,positive
878446.0,"Myriad Genetics, Inc. Sees FY2013 EPS $1.65-1.67 vs $1.58 Est; Sees Sales $595.0M-600.0M vs $583.50M Est",2013-05-07 16:45:00-04:00,MYGN,neutral
878447.0,"Myriad Genetics, Inc. Reports Q3 EPS of $0.46 vs $0.40 Est; Revenue of $156.50M vs $148.25M Est",2013-05-07 16:44:00-04:00,MYGN,neutral
878448.0,"Myriad Genetics, Inc. Reports Q3 EPS of $0.46 vs $0.40 Est; Revenue of $156.50M; Raises Outlook",2013-05-07 16:07:00-04:00,MYGN,neutral
878449.0,US SUpreme Court Seeks Compromise in Myriad's Gene-Patent Case,2013-04-15 11:18:00-04:00,MYGN,positive
878450.0,Myriad Genetics Spikes Higher,2013-04-15 11:17:00-04:00,MYGN,neutral
878451.0,"Myriad Genetics, Pharmamar Announces First Commercial Partnership with New HRD Test",2013-03-26 16:06:00-04:00,MYGN,neutral
878452.0,A Peek Into The Market Before The Trading Starts,2013-03-06 07:18:00-05:00,MYGN,neutral
878453.0,Myriad Genetics Says BRCA Testing Receives Designation Under Affordable Care Act,2013-03-06 07:04:00-05:00,MYGN,positive
878454.0,UPDATE: Oppenheimer Lowers PT on Myriad Genetics on Weaker BRAC Analysis Pricing,2013-03-04 12:47:00-05:00,MYGN,negative
878455.0,"UPDATE: Jefferies Reiterates Buy Rating, Lowers PT on Myriad Genetics on New Medicare Code Values",2013-03-04 09:26:00-05:00,MYGN,positive
878456.0,"Oppenheimer Maintains Perform on Myriad Genetics, Inc., Lowers PT to $29.00",2013-03-04 07:43:00-05:00,MYGN,negative
878457.0,"Jefferies Maintains Buy on Myriad Genetics, Inc., Lowers PT to $31.00",2013-03-04 07:20:00-05:00,MYGN,negative
878458.0,"PetSmart and Other Secular Growth Picks (ACT, MYGN, PETM, HLF)",2013-02-11 12:38:00-05:00,MYGN,positive
878459.0,"Myriad Genetics, Inc. Reports Q2 EPS of $0.42 vs $0.38 Est; Revenue of $149.10M vs $143.71M Est",2013-02-05 16:25:00-05:00,MYGN,neutral
878460.0,"Myriad Genetics Reports Q2 EPS $0.42, Sales $149.1M, Raises FY13 Sales Guidance from $570-585M to $575-585M; Announces $200M Buyback Plan",2013-02-05 16:07:00-05:00,MYGN,neutral
878461.0,"Ladenburg Thalmann Downgraded Myriad Genetics, Inc. to Neutral",2013-02-05 11:37:00-05:00,MYGN,neutral
878462.0,UPDATE: JP Morgan Downgrades Underweight on Myriad Genetics on Risk/Reward  ,2013-01-03 08:40:00-05:00,MYGN,positive
878463.0,"JP Morgan Downgrades Myriad Genetics, Inc. to Underweight, Maintains $26.00 PT",2013-01-03 07:09:00-05:00,MYGN,positive
878464.0,Myriad Genetics Announces Deal with Sanofi,2012-12-10 16:12:00-05:00,MYGN,neutral
878465.0,"UPDATE: Goldman Sachs Downgrades Myriad Genetics to Neutral, Lowers PT",2012-12-03 10:16:00-05:00,MYGN,negative
878466.0,"From Earlier: Mizuho Securities Downgrades Myriad Genetics, Inc. to Neutral, Lowers PT to $30.00",2012-12-03 09:44:00-05:00,MYGN,positive
878467.0,"Goldman Sachs Downgrades Myriad Genetics, Inc. to Neutral, Lowers PT to $26.00",2012-12-03 09:18:00-05:00,MYGN,negative
878468.0,"Goldman Sachs Downgrades Myriad Genetics, Inc. to Neutral",2012-12-03 08:54:00-05:00,MYGN,neutral
878469.0,Myriad Says US Supreme Court to Hear Isolated DNA Patent Case,2012-11-30 16:12:00-05:00,MYGN,positive
878470.0,Gene Patents Get New Review by US Supreme Court in Myriad Case - Bloomberg,2012-11-30 15:25:00-05:00,MYGN,positive
878471.0,Myriad Genetics Resumes Trading,2012-11-30 15:24:00-05:00,MYGN,neutral
878472.0,Myriad Genetics Halted on Circuit Breaker,2012-11-30 15:21:00-05:00,MYGN,neutral
878473.0,Myriad Genetics Spikes Lower,2012-11-30 15:17:00-05:00,MYGN,negative
878474.0,"Jefferies & Company Maintains Myriad Genetics at Buy, Raises PT from $31 to $33",2012-11-06 07:43:00-05:00,MYGN,neutral
878475.0,"Myriad Genetics Raises FY13 EPS Guidance from $1.44-1.48 to $1.50-1.55 vs $1.47 Est, Sales from $550-565M to $570-585M vs $563.4M Est",2012-11-05 16:28:00-05:00,MYGN,neutral
878476.0,Myriad Genetics Reports Q1 EPS $0.36 vs $0.32 Est; Revenues $133.4M vs $129.50M Est,2012-11-05 16:28:00-05:00,MYGN,neutral
878477.0,UPDATE: Bank of America Upgrades Myriad Genetics to Buy on Diversification Strategy  ,2012-10-24 07:20:00-04:00,MYGN,neutral
878478.0,"Bank of America Upgrades Myriad Genetics from Neutral to Buy, Raises PO from $30 to $32",2012-10-24 05:59:00-04:00,MYGN,negative
878479.0,Myriad's HRD Score Detects Loss of DNA Repair Function in Ovarian Cancer,2012-10-10 16:22:00-04:00,MYGN,negative
878480.0,UPDATE: Piper Jaffray Upgrades Myriad Genetics to Overweight on Reimbursement Strategy Confidence  ,2012-10-01 07:12:00-04:00,MYGN,positive
878481.0,"Piper Jaffray Upgrades Myriad Genetics from Neutral to Overweight, Raises PT from $28 to $35",2012-10-01 06:05:00-04:00,MYGN,negative
878482.0,UPDATE: Credit Suisse Initiates Myriad Genetics at Neutral on Overhangs  ,2012-09-25 07:26:00-04:00,MYGN,positive
878483.0,"Credit Suisse Initiates Coverage on Myriad Genetics at Neutral, Announces PT of $28",2012-09-25 06:10:00-04:00,MYGN,positive
878484.0,Myriad Says Utah Medicare Will Add Prostate Test to Next Draft Non-Covered Service LCD,2012-09-24 07:37:00-04:00,MYGN,neutral
878485.0,"Rosetta Genomics (NASDAQ: ROSG), a developer and provider of",2012-08-23 12:55:00-04:00,MYGN,neutral
878486.0,Myriad Genetics Confirms Positive Ruling in Gene Patent Case,2012-08-16 13:07:00-04:00,MYGN,positive
878487.0,Hearing Incorrect Newswire Report on Myriad Patent Decision,2012-08-16 11:26:00-04:00,MYGN,neutral
878488.0,"Myriad Spikes Lower, Hearing Court Decision on Patents",2012-08-16 11:23:00-04:00,MYGN,negative
878489.0,Myriad Genetics Guides FY EPS $1.44-1.48 vs $1.48 Est; Guides FY EPS $550-565M vs $552.3M Est,2012-08-14 16:07:00-04:00,MYGN,neutral
878490.0,Myriad Genetics Reports Q4 EPS $0.34 vs $0.34 Est; Revenues $133M vs $131.85M Est,2012-08-14 16:06:00-04:00,MYGN,neutral
878491.0,Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement,2012-07-26 16:21:00-04:00,MYGN,positive
878492.0,Top 4 Stocks In The Research Services Industry With The Highest Cash,2012-07-25 04:49:00-04:00,MYGN,positive
878493.0,Bio-Rad and Myriad RBM Partner to Commercialize Multiplex Biomarker Kits for Life Science Research ,2012-07-24 16:18:00-04:00,MYGN,neutral
878494.0,"UPDATE: Goldman Sachs Upgrades Myriad Genetics to Buy on Expanded Portfolio, Domestic Bias  ",2012-07-02 10:39:00-04:00,MYGN,negative
878495.0,Goldman Sachs Upgrades Myriad Genetics from Neutral to Buy,2012-07-02 08:20:00-04:00,MYGN,neutral
878496.0,Myriad's Lung Cancer Prognosis Test Shown to Significantly Predict Survival in Early Stage Lung Cancer Patients ,2012-06-04 08:07:00-04:00,MYGN,negative
878497.0,UPDATE: Bank of America Initiates Coverage on Myriad Genetics ,2012-05-11 08:42:00-04:00,MYGN,neutral
878498.0,"Bank of America Initiates Coverage on Myriad Genetics at Neutral, Announces PO of $28",2012-05-11 06:03:00-04:00,MYGN,negative
878499.0,"Jefferies & Company Maintains Myriad Genetics at Buy, Raises PT from $28 to $31",2012-05-02 11:53:00-04:00,MYGN,neutral
878500.0,Myriad Genetics Reports Q3 EPS $0.34 vs $0.32 Est; Revenues $129.8M vs $119.34M Est,2012-05-01 16:32:00-04:00,MYGN,neutral
878501.0,Myriad and Cephalon Enter Into Companion Diagnostic Agreement ,2012-03-28 16:16:00-04:00,MYGN,positive
878502.0,Human-Gene Patent Rehearing Order by High Court in Myriad Case,2012-03-26 10:05:00-04:00,MYGN,neutral
878503.0,US High Court Orders Appeals Panel To Take New Look At Myriad Gene Patents,2012-03-26 10:04:00-04:00,MYGN,neutral
878504.0,Hearing Cowen Positive on Myriad Genetics,2012-03-21 13:11:00-04:00,MYGN,positive
878505.0,Notable Put Options Activity in Myriad Genetics,2012-03-20 13:38:00-04:00,MYGN,neutral
878506.0,Positive Rumors Circulate About Myriad Genetics,2012-03-20 11:43:00-04:00,MYGN,positive
878507.0,Hearing RBC Positive on Myriad Genetics,2012-03-20 11:43:00-04:00,MYGN,positive
878508.0,US High Court Invalidates Prometheus Patents On Medical Diagnostic Tests,2012-03-20 10:19:00-04:00,MYGN,neutral
878509.0,Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk After Prostatectomy  ,2012-02-02 16:07:00-05:00,MYGN,negative
878510.0,UPDATE: Auriga Raises Target on Myriad Genetics to $28,2012-02-01 08:58:00-05:00,MYGN,neutral
878511.0,Myriad Genetics Guides FY2012 EPS $1.24-1.28 vs $1.20-1.25 Est; Revenues $465-475M vs $445-465M Prior,2012-01-31 16:18:00-05:00,MYGN,neutral
878512.0,Myriad Genetics Reports Q2 EPS $0.33 vs $0.31 Est; Revenues $122.80M vs $115.29M Est	 		,2012-01-31 16:06:00-05:00,MYGN,neutral
878513.0,Will Roche's Takeover Bid Help People Predict Diseases?,2012-01-25 12:39:00-05:00,MYGN,positive
878514.0,"End-of-Day Market Summary for January 18, 2012",2012-01-18 16:16:00-05:00,MYGN,neutral
878515.0,Myriad Genetics Acquires Exclusive Rights to RAD51C Gene,2012-01-18 16:11:00-05:00,MYGN,positive
878516.0,Auriga Maintains Buy Rating and $24 PT on Myriad Genetics ,2011-11-02 08:23:00-04:00,MYGN,neutral
878517.0,Myriad Genetics Reports Q1 EPS $0.29 vs $0.28 Est; Revenues $110.5M vs $106.49M Est		,2011-11-01 16:38:00-04:00,MYGN,neutral
878518.0,Top 4 Stocks In The Research Services Industry With The Highest Operating Margin,2011-11-01 04:09:00-04:00,MYGN,positive
878519.0,Benzinga's Top Upgrades,2011-09-23 08:53:00-04:00,MYGN,positive
878520.0,Goldman Sachs Upgrades Myriad Genetics to Neutral ,2011-09-23 07:46:00-04:00,MYGN,neutral
878521.0,Benzinga's Top Upgrades,2011-09-12 07:35:00-04:00,MYGN,positive
878522.0,A Peek Into The Market Before The Trading Starts,2011-09-12 07:21:00-04:00,MYGN,neutral
878523.0,Myriad Genetics Makes Strategic Debt Investment,2011-09-08 16:15:00-04:00,MYGN,negative
878524.0,Myriad Announces New $200 Million Share Repurchase Program,2011-08-15 16:15:00-04:00,MYGN,positive
878525.0,UPDATE: Auriga Lowers PT on Myriad Genetics to $21,2011-08-10 09:28:00-04:00,MYGN,negative
878526.0,"UPDATE: Goldman Sachs Reiterates Sell on Myriad Genetics, Reduces PT to $18",2011-08-10 08:40:00-04:00,MYGN,neutral
878528.0,Goldman Sachs Lowers PT On Myriad Genetics To $18,2011-08-10 06:50:00-04:00,MYGN,negative
878529.0,Myriad Genetics Reports Q4 EPS $0.30 vs $0.29 Est,2011-08-09 16:12:00-04:00,MYGN,neutral
878530.0,Options Brief: Myriad Genetics,2011-07-29 12:20:00-04:00,MYGN,neutral
878531.0,Puts Purchased on Myriad Genetics,2011-07-13 13:32:00-04:00,MYGN,neutral
878532.0,Morgan Stanley Discontinuations 7/6 Continued,2011-07-07 07:19:00-04:00,MYGN,neutral
878533.0,Wednesday's Put/Call Ratio Leaders,2011-06-29 13:54:00-04:00,MYGN,neutral
878534.0,"Options Brief: Myriad Genetics, Inc.",2011-06-29 11:20:00-04:00,MYGN,neutral
878535.0,Top 4 Small-Cap Stocks In The Research Services Industry With The Highest Cash,2011-06-29 00:46:00-04:00,MYGN,positive
878536.0,Benzinga's Top Downgrades,2011-06-15 10:33:00-04:00,MYGN,positive
878537.0,"Auriga Downgrades Myriad Genetics to Hold, Reduces PT to $25 ",2011-06-15 08:52:00-04:00,MYGN,neutral
878538.0,"Auriga Downgrades Myriad Genetics To Hold, Lowers PT To $25",2011-06-15 07:06:00-04:00,MYGN,negative
878539.0,OnDose Study Demonstrates Need for Improved Dosing Approach for Colorectal Cancer Patients,2011-06-09 16:06:00-04:00,MYGN,negative
878540.0,Myriad's PROLARIS Test Shown to Significantly Predict Prostate Cancer Outcome From Needle Biopsy Tissue,2011-06-06 08:09:00-04:00,MYGN,negative
878541.0,"Jefferies Provides Color on Myriad Genetics, Buy",2011-06-01 07:27:00-04:00,MYGN,neutral
878542.0,Morgan Stanley Reiterates Equal-Weight on Myriad Genetics,2011-05-19 07:47:00-04:00,MYGN,neutral
878543.0,Myriad Genetics Licenses Novel Technology From Chronix Biomedical (MYGN),2011-05-10 08:17:00-04:00,MYGN,positive
878544.0,"Goldman Sachs Upgrades PT On Myriad Genetics To $19, Maintains Sell (MYGN)",2011-05-04 12:44:00-04:00,MYGN,neutral
878545.0,Goldman Sachs Has Sell Rating On Myriad Genetics (MYGN),2011-05-04 09:01:00-04:00,MYGN,neutral
878546.0,Morgan Stanley Comments On Myriad Genetics Strong 3Q,2011-05-04 07:45:00-04:00,MYGN,positive
878547.0,Myriad Genetics Reports EPS of $0.31 vs. $0.25 Estimate; Revenues $102.4M vs. $98.11M Estimate (MYGN),2011-05-03 16:25:00-04:00,MYGN,neutral
878548.0,"CEOWORLD TOP 5 higher priced Biotechnology stocks picks- BIIB, CBST, MYGN, REGN and ITMN",2011-05-02 08:56:00-04:00,MYGN,positive
878549.0,"Myriad Genetics Announces Agreement to Acquire Rules-Based Medicine, Pay $80M (MYGN)",2011-04-27 16:25:00-04:00,MYGN,positive
878550.0,Myriad Genetics Announces Agreement to Acquire Rules-Based Medicine (MYGN),2011-04-27 16:24:00-04:00,MYGN,positive
878551.0,J.P. Morgan Comments On Myriad Genetics Risk/Reward Balanced,2011-04-13 08:09:00-04:00,MYGN,neutral
878552.0,Global Hunter Maintains Neutral on Myriad Genetics (MYGN),2011-04-07 08:40:00-04:00,MYGN,neutral
878553.0,Myriad Genetics and BioMarin Pharmaceutical Inc. Enter Into Agreement  ,2011-04-06 16:08:00-04:00,MYGN,positive
878554.0,Goldman Sachs Reports Myriad Genetics Oral Arguments Hold Few Surprises,2011-04-06 08:20:00-04:00,MYGN,negative
878555.0,Pullback in Commodities Takes Pressure Off  03-08-2011,2011-03-08 18:21:00-05:00,MYGN,negative
878556.0,"Top 4 Stocks In The Research Services Industry With The Highest ROE (GPRO, MYGN, ACTG, FORR)",2011-02-28 01:36:00-05:00,MYGN,positive
878557.0,Morningstar's Top Takeover Targets in 2011 (Guest Post),2011-02-22 23:19:00-05:00,MYGN,positive
878558.0,Puts Purchased on Myriad Genetics (MYGN),2011-01-31 11:01:00-05:00,MYGN,neutral
878559.0,"Myriad: EPS In-line, Beats on Revs - Analyst Blog",2011-01-28 12:01:00-05:00,MYGN,neutral
878560.0,"Myriad: EPS In-line, Beats on Revs - Analyst Blog",2011-01-28 11:15:00-05:00,MYGN,neutral
878561.0,Options Brief: Myriad Genetics (MYGN),2011-01-28 11:11:00-05:00,MYGN,neutral
878562.0,Piper Jaffray Raises PT On Myriad Genetics To $20,2011-01-28 07:47:00-05:00,MYGN,neutral
878563.0,Bulls Bet on Myriad Genetics (MYGN),2011-01-25 11:56:00-05:00,MYGN,neutral
878564.0,Calls Purchased on Myriad Genetics (MYGN),2011-01-24 14:43:00-05:00,MYGN,neutral
878565.0,"Benzinga's Top Pre-Market NASDAQ Gainers (CYTX, GLUU, MYGN, HILL)",2011-01-21 08:17:00-05:00,MYGN,positive
878566.0,Myriad Genetics Attracting Heavy Volume After Upgrade (MYGN),2011-01-12 12:03:00-05:00,MYGN,positive
878567.0,Calls Purchased as Myriad Genetics Pops (MYGN),2011-01-12 11:07:00-05:00,MYGN,neutral
878568.0,Myriad Launches Panexia - Analyst Blog,2010-12-21 15:33:00-05:00,MYGN,neutral
878569.0,Myriad Launches Panexia - Analyst Blog,2010-12-21 15:13:00-05:00,MYGN,neutral
878570.0,Myriad Genetics Spikes On Court Ruling -Bloomberg (MYGN),2010-12-17 11:52:00-05:00,MYGN,neutral
878571.0,Myriad Strengthens Portfolio - Analyst Blog,2010-12-09 16:18:00-05:00,MYGN,positive
878572.0,Myriad Strengthens Portfolio - Analyst Blog,2010-12-09 15:54:00-05:00,MYGN,positive
878573.0,ETFs For Biotech M&A Mania,2010-12-06 14:05:00-05:00,MYGN,neutral
878574.0,Myriad Stays Neutral - Analyst Blog,2010-11-30 11:00:00-05:00,MYGN,neutral
878575.0,Myriad Stays Neutral - Analyst Blog,2010-11-30 05:34:00-05:00,MYGN,neutral
878576.0,Myriad Beats by a Penny  - Analyst Blog,2010-11-04 13:54:00-04:00,MYGN,neutral
878577.0,Myriad Genetics Climbs After Earnings (MYGN) ,2010-11-03 12:17:00-04:00,MYGN,neutral
878578.0,Myriad Genetics Rising On Unusual Volume (MYGN),2010-10-13 11:23:00-04:00,MYGN,neutral
878579.0,"Benzinga's Volume Movers (SIGA, AIXG, JOBS, MYGN)",2010-10-13 11:21:00-04:00,MYGN,neutral
878580.0,"Benzinga's Top Upgrades (MYGN, ALU, SFD, AU)",2010-10-13 08:50:00-04:00,MYGN,positive
878581.0,RBC Capital Upgrades MYGN To Outperform,2010-10-13 07:45:00-04:00,MYGN,neutral
878582.0,Triple Negative Breast Cancer Patients May Benefits From Myriads Increased Screening,2010-10-06 09:57:00-04:00,MYGN,negative
878583.0,Triple Negative Breast Cancer Patients May Benefits From Myriads Increased Screening,2010-10-06 09:55:00-04:00,MYGN,negative
878584.0,Potential for Myriad's Bracanalysis - Analyst Blog,2010-10-05 16:33:00-04:00,MYGN,neutral
878585.0,Myriad Genetics Announces $100 Million Stock Repurchase (MYGN),2010-08-31 12:50:00-04:00,MYGN,neutral
878586.0,MYGN Posts Decent FQ4 Despite Weaker Patient Office Visits,2010-08-11 14:15:00-04:00,MYGN,positive
878587.0,"Afternoon Market Update (MYGN, LCC, UAUA, ALK)",2010-08-11 13:45:00-04:00,MYGN,neutral
878588.0,Myriad Genetics Beats Estimates - Analyst Blog,2010-08-11 13:34:00-04:00,MYGN,neutral
878589.0,Myriad Genetics Exceed Estimates But Guidance Is Mixed,2010-08-11 11:11:00-04:00,MYGN,neutral
878590.0,A Peek Into The Market Before The Trading Starts,2010-08-11 09:11:00-04:00,MYGN,neutral
878591.0,Citi Lowers Target On Myriad Genetics (MYGN),2010-08-11 08:48:00-04:00,MYGN,negative
878592.0,"Benzinga’s Top Downgrades (CRK, AOSL, MYGN, TSCO)",2010-08-11 07:06:00-04:00,MYGN,positive
878593.0,Global Hunter Downgrades MYGN To Neutral ,2010-08-11 06:18:00-04:00,MYGN,neutral
878594.0,Myriad Genetics Reports Earnings; Updates Guidance (MYGN),2010-08-10 16:39:00-04:00,MYGN,neutral
878595.0,Calls Purchased on Myriad Genetics (MYGN) ,2010-07-14 14:01:00-04:00,MYGN,neutral
878596.0,Myriad Genetics Falling On Heavy Volume After J.P. Morgan Downgrade (MYGN),2010-07-09 12:23:00-04:00,MYGN,negative
878597.0,MYGN Slips On Downgrade In Rating,2010-07-09 10:24:00-04:00,MYGN,neutral
878598.0,"Benzinga’s Top Downgrades (PT, BBY, CNI, MYGN)",2010-07-09 07:53:00-04:00,MYGN,positive
878599.0,Calls Purchased on Myriad Genetics (MYGN) ,2010-06-28 13:20:00-04:00,MYGN,neutral
878600.0,Calls Purchased on Myriad Genetics (MYGN) ,2010-06-14 15:35:00-04:00,MYGN,neutral
878601.0,"Top 5 Small-Cap NASDAQ Stocks In The Healthcare Sector With The Highest Cash (ONXX, ISIS, MYGN, CBST, VPHM)",2010-06-07 06:36:00-04:00,MYGN,positive
878602.0,Myriad Genetics (MYGN) Downgraded To Neutral At Piper Jaffray ,2010-05-05 12:15:00-04:00,MYGN,neutral
878603.0,"News Summary (MYGN, ALK¸ CTL, Q) ",2010-05-05 10:21:00-04:00,MYGN,neutral
878604.0,"Benzinga’s Top Pre-Market Losers (ITMN, MYGN, GRMN, AVNR, MPEL)",2010-05-05 08:55:00-04:00,MYGN,negative
878605.0,Piper Jaffray Downgrades MYGN To Neutral,2010-05-05 08:33:00-04:00,MYGN,neutral
878606.0,"Top 5 Mid-Cap Stocks In The Healthcare Sector On The NASDAQ With The Lowest PEG Ratio (UTHR, WCRX, MYGN, ENDP, TLCR)",2010-05-05 06:22:00-04:00,MYGN,negative
878607.0,"Benzinga's After Hours Decliners (MYGN, ITMN, TRLG)",2010-05-04 17:45:00-04:00,MYGN,neutral
878608.0,Myriad Genetics Falls,2010-03-30 10:22:00-04:00,MYGN,neutral
878609.0,"Benzinga’s Top Pre-Market Losers (TNDM, GNVC, HPJ, MYGN)",2010-03-30 08:19:00-04:00,MYGN,negative
878610.0,"U.S. Equity Market Preview (BJ, BBI, CEPH, DHR, MYGN)",2010-03-30 07:14:00-04:00,MYGN,neutral
878611.0,"Myriad Genetics Falling In After Hours (MYGN, CEPH)",2010-03-29 18:44:00-04:00,MYGN,negative
878612.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,MYGN,positive
878613.0,"Benzinga’s Volume Movers (APKT, AUXL, NETL, MYGN, ACOR)",2010-02-03 14:08:00-05:00,MYGN,neutral
878614.0,Pharma Stocks Dive On Missed Expectations,2010-02-03 11:55:00-05:00,MYGN,negative
878615.0,MYGN To Outperform In The Short Term On Strong December Quarter Results,2010-02-03 10:20:00-05:00,MYGN,positive
878616.0,"Benzinga's After Hours Gainers (AOL, SU, NETL, MYGN)",2010-02-02 18:48:00-05:00,MYGN,neutral
878617.0,2010 Fund Performance Period 1,2010-02-02 16:23:00-05:00,MYGN,neutral
878618.0,"Stocks That Created New 52-Week Lows (CRIC, CCBP, GIGM, MYGN, RUTHR)",2010-01-25 15:46:00-05:00,MYGN,positive
878619.0,"Bookkeeping: Weekly Changes to Fund Positions Year 3, Week 24",2010-01-18 15:21:00-05:00,MYGN,neutral
878620.0,Reviewing Recent Sales,2010-01-15 15:10:00-05:00,MYGN,neutral
878621.0,Bookkeeping: Closing Human Genome Sciences (HGSI),2010-01-12 12:44:00-05:00,MYGN,neutral
878622.0,Bookkeeping: Closing Myriad Genetics (MYGN) as Oppenheimer Analyst Brings Out the Hammer,2010-01-12 10:34:00-05:00,MYGN,neutral
878623.0,Partnership Likely To Boost Myriad Genetics’ (MYGN) Sales By An Additional 15%,2010-01-07 12:53:00-05:00,MYGN,positive
878624.0,"Bookkeeping: Weekly Changes to Fund Positions Year 3, Week 21",2009-12-28 08:00:00-05:00,MYGN,neutral
878625.0,Bookkeeping: Restarting Myriad Genetics (MYGN),2009-12-23 11:11:00-05:00,MYGN,neutral
878626.0,"Likely Torch Bearers In The Market If The Economic Recovery Sustains, WSFS, PEI, IDTI, MCHP, MWA  ",2009-11-30 10:13:00-05:00,MYGN,neutral
878627.0,"Benzinga’s Top Upgrades (PALM, TRST, MYGN, COLM, SFD, FLR)",2009-11-11 11:16:00-05:00,MYGN,positive
878628.0,Bookkeeping: Closing Myriad Genetics (MYGN) as Earnings Fail to Provide a Charge,2009-11-05 10:55:00-05:00,MYGN,negative
878629.0,"Cramer Talks About MYGN, ERTS, VIA, NSC, BNI",2009-11-04 08:22:00-05:00,MYGN,neutral
878630.0,"Bookkeeping: Adding Back some Atheros Communciations (ATHR), Cutting Much of Myriad Genetics (MYGN)",2009-10-20 10:39:00-04:00,MYGN,negative
878631.0,"Top 5 Stocks with Best ROE (FSLR, GGG, IDCC)",2009-10-05 05:44:00-04:00,MYGN,positive
878632.0,Limit Buy Order List,2009-09-27 20:22:00-04:00,MYGN,neutral
878633.0,Bookkeeping: Restarting Position in Myriad Genetics (MYGN),2009-09-25 12:15:00-04:00,MYGN,neutral
878634.0,"WallStSense.com Fundamental & Technical Coverage of MYGN, JRCC, QGEN, QLGC, MDRX and OVTI",2009-08-18 06:29:00-04:00,MYGN,neutral
